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ABSTRACT
One way of targeting gene expression in vivo is to control transcription using a tissue- 
specific regulatory system. Tissue-specific promoters or enhancers are in use in 
transgenic animals and could be utilized in medicine for gene therapy. At present the 
usual method for selection of a tissue-specific promoter is to identify a gene, which is 
expressed at unusually high level in the target tissue, and then to use the promoter for 
this gene to drive expression of another therapeutic gene in the target tissue. This 
approach is logical but does not always lead to high levels of gene expression. A 
second approach is to investigate the scope for discovery of synthetic specific promoters 
using a target tissue. In the present thesis we used both approaches to design plasmid 
DNA expression vectors that would carry liver-specific promoter/enhancer linked to a 
reporter gene (i.e. luciferase). We then transfected these vectors to both liver-derived 
and non-liver cell lines and then evaluated the liver-specificity of each construct by 
measuring the basal level expression of the reporter gene (i.e. luciferase activity) in both 
cell lines. The first part of this thesis dealt with literature survey using gene bank 
database, Vector NTI program software, and TFSEARCH algorithms to identify some 
of the transcription factors that are highly expressed in the liver. The research revealed 
the presence of four families of liver-enriched transcription factors, which are 
hepatocyte nuclear factor-1 (HNF-1), the CCAAT/enhancer binding protein (C/EBP), 
the hepatocyte nuclear factor-3 (HNF-3) and the hepatocyte nuclear factor-4 (HNF-4). 
Once this phase of the project has been completed, the HNF-4 was selected from the 
above group of liver-enriched transcription factors and used to design new synthetic
enhancers by inserting a tandem array of 1, 3 or 5 repeats o f the HNF-4 binding site 
upstream of the SV40 promoter linked to the luciferase reporter gene within an Epstein- 
Barr virus (EBV)-based vector, p706. The results of transfection revealed that 
unexpectedly the HNF-4 binding sites in these constructs act as a repressor rather than 
enhancer of the liver-specific expression of the luciferase gene. The second approach 
was to use the promoter region of the liver-enriched heme oxygenase 1 (HO-1) gene to 
drive the expression of the luciferase reporter gene to mimic a therapeutic gene in the 
target tissue. The strategy involved the identification of the c/s-acting elements that 
regulate basal human HO-1 gene expression by using EBV-based reporter plasmids 
containing deletions within the specific regions of 4.7 kb of the human HO-1 5’- 
flanking region linked to the luciferase gene. Basal level expression of these constructs 
was measured following transient transfection in both liver-specific HepG2 (human 
hepatoma) and non-liver HtTA-1 (Hela-derivative) cell lines. From these 
investigations, it was found that the expression of the luciferase reporter in 4.7 kb of the 
5’-flanking region of the human HO-1 is preferentially higher in HepG2 cells when 
compared to the non-liver cell line HtTA-1, so that the 5’-flanking region of the HO-1 
gene can be used for the design of liver-specific gene delivery systems. Furthermore 
one positive regulatory region at position -4080 to -3650 was identified that 
specifically functioned in HepG2 cells but not in HtTA-1 cells. A negative regulatory 
region was also found at position -380 to +1 that only functioned in HepG2 cells. 
There are many putative regulatory elements in these positive and negative regulatory 
regions that need further investigations. An analysis of the features of the 5’-flanking
region of the human HO-1 gene should provide pointers to a better understanding o f the 
mechanism of tissue preferential expression and tissue-specific targeted gene delivery.
CHAPTER 1 INTRODUCTION
1.1. Gene Expression
A gene is a repository of information, that holds the instructions for making one of 
the key molecules o f life i.e. RNA. The sequence of bases in the RNA molecule is 
dependent on the sequence of bases in the gene (Weaver et ol., 1997). Thus, most 
genes are essentially blueprints for the building o f individual cellular constituents. 
The coordinated program of protein synthesis from the genetic blueprint and the 
means of controlling its execution are called gene expression. Gene expression 
involves two stages for producing protein from information in a DNA gene (Lewin, 
1997). The first step is the synthesis of RNA, which is complementary to one o f the 
strands o f DNA, this is called transcription. The second step is translation, where 
the information in the RNA is used to make a protein (Weaver et al.9 1997).
1.1.1. Regulation of Transcription in Prokaryotes
The transcription unit is a segment o f DNA (template) that is transcribed into RNA. 
Transcription occurs in three stages initiation; elongation and termination to 
synthesise RNA on a template of DNA. Figure 1.1. shows the process of 
transcription and the gene associated with various non-transcribed DNA elements 
such as promoters, enhancers and RNA polymerase (Adams et al., 1986).
The RNA polymerase enzyme recognises a region called a “promoter”, which lies 
just upstream from the gene. The RNA polymerase binds tightly to the promoter 
region and causes separation of the two DNA strands within the promoter region, 
(initiation). Then the polymerase starts building the RNA chain (elongation).
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During the elongation stage of transcription the enzyme moves along the DNA 
extending the growing RNA chain.
Finally, in the termination stage the terminators in conjunction with RNA 
polymerase loosens the association between the RNA product and the RNA 
polymerase and DNA transcription is terminated (Hawkins, 1996).
(1) Initiation:
(a) RNA polym erase binds 
to promoter:














Figure 1.1. Transcription processes with three stages initiation, elongation and 
termination to synthesis RNA from a template of DNA (adapted from Weaver et al., 
1997).
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1.1.2. Regulation of Transcription in Eukaryotes
Transcription in Eukaryotic cells is divided into three classes. A different RNA 
polymerase within the nuclei o f cells transcribes each class:
- RNA polymerase I transcribes ribosomal RNA ”rRNA”.
- RNA polymerase II transcribes messenger RNA “mRNA”.
- RNA polymerase III transcribes transfer RNA “tRNA” (Lewin, 1997).
1.1.3. Promoter
A promoter element is a region o f DNA involved in the binding of RNA polymerase 
to initiate transcription.
Since there are three different RNA polymerases in eukaryotic nuclei, so there are 
three different kinds of promoters. RNA polymerase I and II recognise one kind of 
promoter each, but RNA polymerase III uses two different classes of promoters. 
Those promoters rely on proteins called transcription factors, which are not 
themselves part o f the RNA polymerase. There are two classes o f transcription 
factors
(a)- General transcription factors and (b)- Gene-specific transcription factors called 
“gene activators” (Paule, 1981; Lewis et a l , 1982). These classes are discussed in 
detail in section 1.1.4.1. and 1.1.4.2.
1.1.3.1. Promoters Recognised by RNA Polymerase II
The promoters for RNA polymerase II consist o f a number o f sequence elements 
required for accurate and efficient initiation o f transcription (Chambon et al., 1984).
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One important element is the TATA box: This is an A-T rich sequence element with 
the consensus sequence TATAAAA, found closest to the transcription start site, 
approximately at position -30  (see Figure 1.2.) and its function is to fix the location 










Figure 1.2. Diagram of the promoter region for RNA polymerase II (adapted from 
Adams et al., 1986).
Another promoter element recognized by RNA polymerase II is the CCAAT box, 
found about fifty base pairs further upstream of the start site, approximately at 
position -75. This box has the consensus sequence o f GGCCAATCT and it 
functions as part o f the promoter in promoting efficient initiation.
Another upstream promoter element, called the enhancer element is a 25 bp 
sequence that is repeated three times at position -90  bp just upstream from the 
TATA box. Each of these 25 bp repeats contains two copies o f GC box with the 
sequence GGGCGG (Glick et al., 1998) as shown in Figurel.2.
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1.1.3.2. Promoter Recognised by RNA Polymerase I
RNA polymerase I transcribes only the genes for rRNA, from a single type of 
promoter. The rRNA promoter in human cells consists of two important DNA 
elements (Lewin, 1997; Hawkins, 1996).
(a)-The core element that is located between positions -45 and +20 and is 
sufficient for transcription to initiate.
(b)-The upstream control element (UCE) that is located between position -156 




-156 -107 -45 +1 +20
Figure 1.3. The human rRNA promoter, which consists of two DNA elements, UCE 
(green) and CORE (red), both of which are important for efficient transcription by 
RNA polymerase I.
1.1.3.3. Promoters Recognised by RNA Polymerase III
The promoters for the genes transcribed by RNA polymerase III do not lie in the 5 -  
flanking sequences of the gene but within the coding region of the gene itself. This 
region lies between positions +50 and +83 of the transcribed sequence. The 




Transcription o f eukaryotic genes depends not only on RNA polymerase binding to 
a promoter but also on a collection of trans-acting proteins called transcription 
factors (TF) that interact with promoters and enhancers. They appear to be 
important for the formation o f a stable initiation complex with the template and the 
accurate initiation o f transcription (Adams et al., 1986).
There are two classes of such factors: general transcription factors, and gene specific 
transcription factors (Weaver et al., 1997).
1.1.4.1. General Transcription Factors
1.1.4.1.1. RNA Polymerase II Transcription Factors
The general transcription factors that are involved in transcription of most 
polymerase II genes interact with the region that extends upstream from the TATA 
box sequence (Hawkins, 1996).
The general transcription factors are: TFIIA, TFIIB, TFIID, TFIIE, TFIIF and 
TFIIH.
In higher eukaryotes including mammals the TFIID contains several polypeptide 
subunits as TATA box-binding protein “TBP” or TATA box-binding protein 
associated factors “TAF’s”.
The preinitiation complex shown in Figure 1.4. is primed to initiate transcription 







Figure 1.4. The class II preinitiation complex of RNA polymerase II, containing 
TFIIA (A), TFIIB (B), TFIID (D), TFIIE (E), TFIIF (F), and TFIIH (H) bound to the 
TATA-box and TBP (adapted from Weaver et al., 1997).
1.1.4.1.2. RNA Polymerase I Transcription Factors
RNA Polymerase I requires two transcription factors:
(a)- Upstream binding factor “UBF” that binds in a sequence-specific manner to 
related sequences in the core promoter.
(b)-“S L l” that does not by itself have specificity for the promoter, but once 
UBF1 has bound, SL1 can bind to the region of DNA. Once both factors are 
bound to form the preinitiation complex, RNA polymerase I can bind to the core 






Figure 1.5. The class I preinitiation complex of RNA polymerase I. The two parts 
of the rRNA promoter (UCE and Core) are represented by white boxes (adapted 
from Weaver et al., 1997).
1.1.4.1.3. RNA Polymerase III Transcription Factors
Three transcription factors are involved in transcription by RNA polymerase III: 
TFIIIA, TFIIIB and TFIIIC. TFIIIA is a member of an interesting class of zinc 
finger proteins, TFIIIB is the true transcription initiation factor for RNA polymerase 
III and consists of TBP and two other proteins. TFIIIC is a large protein complex 
(>500 KD) bound to the internal promoter and by protein-protein interaction, allows 
TFIIIB to bind near to the transcription start site (Glick et al., 1998).
1.1.4.2. Gene-Specific Transcription Factors
In addition to the general transcription factors there are a group of gene-specific 
factors. Three main types of protein structures are involved in interactions of the
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transcription factor with the DNA (Hawkins, 1996). These are “Zinc fingers”, 
“Helix turn helix”, and “Leucine zippers”.
I.I.4.2.I. Zinc Fingers
These are sequence o f about 9-13 amino acid residues predicted to be finger-shaped 
because each of these domains binds zinc ion as shown in Figure 1.6. The zinc 
finger binds to the major groove o f DNA and interacts with about 5 bases of the 
template. The specific binding of these proteins to particular sites on DNA is 
determined by certain residues either in the fingers or immediately adjacent to them 
(Hawkins, 1996; Weaver et al., 1997).
9
Figure 1.6. Schematic diagram of two adjacent zinc fingers, each finger is bound to 
four amino acids: two cysteines (yellow) and two histidines (blue), holding the 
finger in the correct conformation for DNA binding (adapted from Weaver et al., 
1997).
I.I.4.2.2. Helix-Turn-Helix
This is another structural motif commonly found in DNA binding proteins in both 
prokaryotes and eukaryotes. It consists of a-helix containing eight amino acid 
residues. The proteins containing this motif are frequently on one side of the helix 
making Van der Waals contacts with the bases.
I.I.4.2.3. Leucine Zipper: ‘bZIP domains’
In the leucine zipper the DNA binding proteins are a-helices containing a leucine 
residue in every seventh position. There are generally four leucine residues on each 
helix and this structure has been christened a “Leucine Zipper” (Alberts et al., 
1989). This m otif is described in more detail in section 1.1.5.1.5.
1.1.5. Tissue/Organ Enriched Transcription Factors
Most o f the proteins accounting for organ functions are expressed mainly or 
exclusively within a specific set o f tissue-specific cells which therefore provide an 
attractive model for studying tissue specific gene expression (Tronche et al., 1992). 
Present knowledge of transcriptional regulation in organs has been derived from the 
study of two regulatory elements, the analysis o f promoter and far-upstream 
enhancers of genes selectively expressed in adult tissues using transient transfection 
in tissue cell lines. The binding sites o f the organ-enriched and ubiquitous 
transcription factors for these two elements are clustered within short regions 
however, transcription o f a given gene in adult tissues appears to require a particular 
combination of multiple transcription factor binding sites which are defined as 
combinatorial controls (Cereghini, 1996). Some o f these nuclear factors controlling 
gene expressed in adult tissue, are involved in the early events o f organ 
differentiation and development. Such factors therefore play critical roles in 
maintaining the expression of organ-specific functions in the adults.
Organ/tissue specific gene expression has been recently used as a tool for 
development of organ/tissue specific gene therapy protocols. Such gene therapy 
employs well-understood specific transcription factor binding elements as building 
blocks for generation o f organ/tissue-specific synthetic promoters. For example
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skeletal muscle is an attractive target for somatic gene therapy because of its long 
life span, ease o f accessibility for intramuscular injections and large capacity for 
protein synthesis and secretion (Tripathy et a l, 1996; Hasse, 1997). However, 
relatively low levels of expression from naturally occurring promoters have limited 
the use o f muscle as a gene therapy target. To counteract this limitation, recently 
Draghia-Akli and coworkers (1999) have developed a strategy to isolate synthetic 
muscle-specific promoters that will have both high in vitro and in vivo 
transcriptional activity. The strategy involved random assembling of several 
myogenic regulatory elements i.e. serum response element “SRE”, myocyte-specific 
enhancer binding factors “MEF-2”, “MEF-1” and transcription enhancer factor-1 
“TEF-1” into synthetic promoter recombinant libraries. This was followed by the 
screening o f the libraries that resulted in isolation o f several artificial novel 
promoters whose transcriptional potencies in terminally differentiated muscle 
greatly exceeded those o f natural myogenic and viral gene promoters (Li et al., 
1999).
Another potential target for organ-specific gene therapy is the liver. This has led to 
extensive study of the hepatic transcription regulatory network notably the liver- 
enriched transcription factors. Indeed experiments using cDNA library from mouse 
liver poly(A)+ RNA that was then differentially screened with poly(A)+ RNA from 
liver and non-liver cells provided strong evidence that the predominant control of 
liver-specific gene expression resides at the level of transcription (Derman et al, 
1981; Aran et al, 1995). Clones proven to be liver-specific were picked and used as 
templates for hybridization with radioactive RNA newly transcribed in vitro in 
nuclei isolated from liver and non-liver tissues. The hybridization signals obtained 
with RNA synthesized with liver nuclei were at least 10 times more intense than
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those obtained with nuclei from other tissues. Because the cDNA clones 
represented an unbiased population of transcripts, the findings led to the conclusion 
that liver-specific gene expression is primarily a consequence of transcriptional 
regulation (Derman et a l , 1981).
Since the key proteins for liver function are expressed mainly in hepatocytes, much 
attention has been given to understand the mechanism of transcription regulatory 
network in these hepatic cells. The transcription rate o f genes encoding liver- 
specific proteins is distinctly higher in hepatocytes as compared with other cell types 
(Powell et a l , 1984). Furthermore, the transcription o f several hepatic genes is 
specifically activated in hepatocytes during liver development and later modulated 
depending on extracellular stimulation (Schmid and Schulz, 1990; Shiojori et a l , 
1991).
1.1.5.1. Liver Enriched Transcription Factors
Transient transfection assays in which the introduced gene does not integrate into 
the genome have been instrumental in identifying the regulatory sequences in DNA 
that confer liver-specific gene expression. Analyses performed on a wide variety of 
genes that code for entirely different proteins show shared regulatory sequences. 
Moreover, characterization o f the regulatory sequences of a number o f genes has 
shown that each gene contains a combination o f some or all o f the liver-specific 
shared motifs (Benvenisty and Reshef, 1991; Aran et al, 1995). It is this 
combination of ds-regulatory elements rather than a single element that appears to 
be required for liver-specific gene expression. Finally, these shared motifs bind
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distinct cognate liver-enriched transcription factors and have aided in isolating and 
characterizing these factors (De Simone and Cortese, 1991).
Over the last few years a number of transcription factors have been identified that 
have important roles in regulating liver development and differentiation. These 
specific transcription factors use novel mechanisms for gene expression that 
ultimately direct cell differentiation (Duncan, 2000).
So far, six families of liver-enriched transcription factors were identified that 
participate in the expression of liver genes in the adult hepatocytes i.e. hepatocyte 
nuclear factor-1 “HNF-1”, hepatocyte nuclear factor-3 “HNF-3”, hepatocyte nuclear 
factor-4 “HNF-4”, hepatocyte nuclear factor-6 “HNF-6”, CCAAT/enhancer binding 
protein “C/EBP”, and D-binding protein “DBP” (Cereghini, 1996; Schrem et al, 
2002). The analysis o f the tissue distribution of these factors and the determination 
of their hierarchical relations have led to the hypothesis that the cooperation o f liver- 
enriched transcription factors with the ubiquitous transactivating factors is 
necessary, and possibly even sufficient, for the maintenance o f liver-specific gene 
transcription (Hayashi et a l , 1999).
1.1.5.1.1. Hepatocyte Nuclear Factor-1 “HNF-1”
Hepatocyte nuclear factor-1 (HNF-1) mRNA and proteins although enriched in 
liver, can also be found in kidney tissues, intestine, and pancreas at significant 
different levels (Rey-camos et al, 1991). HNF-1 is composed o f H N F -la  and 
HNF-1 (3 hetero- and homo-dimers. These homeoproteins share identical DNA- 
binding domains but have different transcriptional activation properties (Kuo et a l , 
1991; Song et a l , 1998). Interestingly, H N F-la, but not HNF-1 p, is expressed in 
the liver. Under physiologic conditions as well as in transfection experiments with
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H N F-la  and HNF-1 (3, stable homodimer formation can be found in the liver, 
whereas in other organs, heterodimers are also detected. From these data it is 
assumed that the extent of heterodimerization might be regulated in a tissue-specific 
manner. Furthermore, it could be shown that exclusive expression o f HNF-1 p is 
associated with repression o f a subset of hepatocyte-specific genes in the 
dedifferentiated hepatocyte cell line C2, in differentiated F9 cells, in somatic hybrids 
between hepatocytes and fibroblasts, and in the lung (Mendel et a l , 1991a).
H N F-la  is one of the first liver-enriched transcription factor, to be identified by its 
interaction with an essential sequence for liver-specific transcription of the p- 
fibrinogen, albumin, and a  1-antitrypsin promoters (Hardon et al., 1988). The 
binding site o f H N F-la was found in more than 30 different liver-specific genes 
with the consensus sequence of 15 bp containing an inverted repeat of 
GGTTAATNATTAAC.
The genes regulated by H N F -la  encode products involved in diverse metabolic 
functions, including synthesis of seroproteins, carbohydrate metabolism, and 
detoxification (Cereghini, 1996). For example H N F -la  is one o f the most important 
transactivators of liver-specific albumin transcription (Maire et a l , 1989). It also 
acts as an accessory factor to enhance the inhibitory action o f insulin on mouse 
glucose-6-phosphatase gene transcription (Streeper et a l , 1998). H N F-la  is also an 
accessory factor required for activation of glucose-6-phosphatase gene transcription 
by glucocorticoids (Lin et al., 1998). Several lines of evidence point to a direct 
transactivation of the mouse ferrochelatase promoter by H N F-la  in the liver 
(Muppala et al., 2000).
The structure of H N F -la  can be described as a homeodomain-containing 
transcription factor that is located within its first 281 amino acids. It is unique
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among the vertebrate homeodomain-containing proteins in that it dimerizes in the 
absence of its DNA recognition sequence (Mendel et al., 1991b). It is characterized 
by a tripartite structure, in which the amino acids 1 to 31 are necessary and sufficient 
for dimerization of protein, as shown in Figure 1.7. This tripartite structure is 
composed of an amino-terminal dimerization domain (domain A), specific domain 
conferring a specific sequence (domain B) and a typical homeodomain structure 
(domain C). H N F-la requires transactivation to the carboxy-terminal region and in 
ex vivo situation, this appears to be achieved by the combined action of two regions: 
The activation domain I (ADI) rich in serine and the activation domain III (ADIII) 
rich in glutamine (Ceska et al., 1993).
Dimerization B-Domain Homeodomain Transcriptional Activation
ADII ADIII ADI
1 I I
31 100 184 198 281 318 440 506 546 i 28
N-Terminal C-Terminal
Figure 1.7. Schematic diagram representation of the structure of H N F-la 
transcription factor.
I.I.5 .I.2 . Hepatocyte Nuclear Factor-4 “HNF-4”
Hepatocyte nuclear factor-4 (HNF-4) is a liver-enriched transcription factor 
but it is also expressed at significant levels in primary blastocyst endoderm, 
intestinal and kidney cells (Hall et al., 1995). It belongs to the zinc finger
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family. It is a member of the steroid hormone receptor superfamily, and it 
binds DNA as a dimer (Plengvidhya et al., 1999).
The carboxyl terminal region of HNF-4 contains a large hydrophobic region 
“133-373” reminiscent of the dimerization and ligand binding domain of other 
receptors (Cereghini, 1996) as shown in Figure 1.8.
N-Terminal C-Terminal
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Figure 1.8. Comparison of conserved region of HNF-4, between rat HNF-4 
and the Drosophila homologue HNF-4 (D).
In addition, HNF-4 contains a zinc finger DNA binding domain at position 50 
to 116. HNF-4 possesses a proline-rich region at the carboxyl terminus and 
three serine-threonine regions located throughout the molecule. HNF-4 is 
phosphorylated at tyrosine, serine and to a lesser extent at threonine residues 
(Cereghini, 1996). The binding site of this factor i.e. KGCWARGKYCAY is 
considered as an activator of the gene apolipoprotein-C III (ApoC III) in 
humans. However, in the rat the gene activator is HNF-1. The composition of 
the binding site of this human factor between position “-82 to -69” is as
17
follows: TGACCTTTGCCCAG (Kel et a l , 1995; Tian et a l , 1991). Such 
binding site is required for the hepatoma-specific expression o f H N F-la, 
suggesting its participation in liver development.
HNF-4 is also involved in the regulation of several genes such as those 
encoding for pyruvate kinase, the blood clotting factor (factor IX), medium 
chain acyl-coenzyme A dehydrogenase, tyrosineamine-transferase, ornithine 
transcarboxylase, cellular retinal-binding protein II, transferrin, ApoA I, ApoA 
II, ApoB I, and ApoC III (Hall et a l , 1995; Tian et a l , 1991; and Mietus- 
snyder et al, 1992). It is also involved in the expression of the hepatitis B 
virus enhancer, the a  1-antitrypsin and transthyretin genes (Flodby et a l , 1993; 
Costa, et a l, 1989).
HNF-4 contains two transactivation domains, designated activation function-1 
(AF-1) and activation function-2 (AF-2), which activate transcription in a cell 
type-independent manner. Deletion of AF-1 results in 40% reduction o f the 
HNF-4-mediated activation (Hadzopoulo-Cladaras et al., 1997). HNF-4 binds 
to the AF-1 portion o f the region between “-81 to -62”. AF-1 is considered as 
a liver enriched transcription factor, that binds to a region of the ApoB 
promoter “-81 to -52”, which is critical to the expression o f 
phosphenolpyruvate carboxy kinase gene in hepatocytes.
Studies with in vitro translated HNF-4 protein show that it binds to its 
recognition site as a dimer, and cotransfection assays indicate that it activates 
transcription in a sequence-specific fashion in non-hepatic (Hela) cells (Sladek 
et a l , 1990).
HNF-4 mRNA and protein level are not affected in rat liver after partial 
hepatectomy (Flodby et al., 1993). However, following hepatectomy some
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cytokines such as tumor necrosis factor (TNF-a), interleukin-1 (IL-1) and 
interleukin-6 (IL-6) are believed to induce HNF-4 factor, and other factors 
such as PHF (post-hepatectomy factor)/(nuclear factor kappa B) NF-kB and 
STAT-3 (signal transducer and activator of transcription 3) (Diehl et al., 
1996).
HNF-4 subfamily members include HNF-4 a , HNF-4 p and HNF-4y:
• H N F-4a (gene symbol, TCF14) is believed to play an important role in 
maintaining hepatocyte specific differentiation. It is a positive 
regulator and activator o f H N F-la  expression (Yamagata et al., 1996), 
and it is expressed at the earliest stage o f liver formation.
Moreover, HNF-4a is expressed in the mammalian kidney and 
digestive tract (Sladek et al., 1990; Holew et a l, 1997). Disruption of 
the HNF-4a gene leads to an early embryonic lethal phenotype 
associated with a failure o f differentiation o f the visceral endoderm 
(Spath et al., 1997).
HNF-4a is expressed in high levels during the liver development and 
differentiation phase in mice (Duncan et al., 1994).
Further complexity o f gene control by HNF-4a transcription factors 
can be anticipated by the differential splicing of the 10 initially 
identified exons of the HNF-4<z gene (Nakhei et a l, 1998). Thus, so 
far, seven distinct splice variants have been identified in human and 
murine cDNA samples. HNF-4a-l represents the initially identified 
transcript, whereas HNF-4a2 through HNF-4a7 are the splice variants 
identified subsequently (Kritis et a l, 1996; Furuta et a l, 1997; Nakhei 
etal., 1998).
In 1998, Hertz and coworkers published the discovery o f several 
ligands for HNF-4 with agonistic and antagonistic effects on HNF-4a 
transcriptional activity. It could be demonstrated that long-chain fatty 
acids directly modulate the transcriptional activity o f HNF-4a by 
binding as their acyl-Coenzyme A thioesters to the ligand-binding 
domain o f HNF-4a (Hertz et al., 1998).
• HNF-4P was first identified in Xenopus and showed distinct activation 
and expression profiles in oogenesis and embryogenesis of Xenopus 
laevis (Holew et a l, 1997).
• HNF-4y is highly homologous to HNF-4a showing almost complete 
amino acid identity in the DNA- and ligand-binding domains as shown 
in Figure 1.9. (Drewes et al., 1996). However Northern blot analyses 
reveal that HNF-4y is expressed in the kidney, pancreas, small 
intestine, testis and colon but not in the liver, whereas HNF-4a mRNA 











Figure 1.9. Schematic representation of the HNF-4y cDNAs. The black boxes 
represent the cDNA regions homologous to the HNF-4a cDNA (A and B).
The gray box represents the new 5' sequence (B).
Recent studies have demonstrated that HNF-4 could also act as a negative 
regulator of several mammalian genes such as mitochondrial HMG-Coenzyme 
A synthase, acetyl-Coenzyme A oxidase, peroxisome proliferator-activated 
receptor alpha (PPAR-a) and rat arginase (Rodriguez et al., 1998; Nishiyama 
et al., 1998; Chowdhury et al., 1996).
I.I.5 .I.3 . Hepatocyte Nuclear Factor-3 “HNF-3”
The Hepatocyte nuclear factor-3 (HNF-3)/forkhead (fkh) family contains a large 
number of transcription factors and folds into a winged helix motif (Marsden et al., 
1998; Jin et al., 1999). The HNF-3 gene subfamily is composed of three proteins 
(a, P and y) that mediate hepatocyte-enriched transcription of numerous genes
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whose expression is necessary for organ function (Samadani and Costa, 1996). All 
three transcription factors share strong homology in the winged-helix/fork head 
DNA-binding domain (region I) that overlaps with the nuclear localization signal 
(Qian and Costa, 1995). HNF-3a, -p, and -y are able to recognize the same DNA 
sequence (Samadani & Costa, 1996; Pani et a l, 1992 a,b). They also possess two 
similar stretches o f amino acids at the carboxy terminus (regions II and III) and a 
fourth segment o f homology at the amino terminus (region IV) (Pani et al, 
1992a,b).
The HNF-3 proteins demonstrate homology with the Drosophila homeotic gene 
‘fkh’ in regions I, II and III, suggesting that HNF-3 may be its mammalian 
homologue (Pani et a l, 1992a). Experiments using site-directed mutagenesis within 
regions II and III (amino acids 361-458) of HNF-3p demonstrated their importance 
for transactivation. In cotransfection assays with expression vectors that produced 
different truncated HNF-3 p proteins, amino-terminal sequences defined by 
conserved region IV also contributed to transactivation, but region IV activity 
required the participation o f the region II-III domain (Pani et al, 1992a).
A number of liver-specific genes that are predominantly expressed in the liver are 
positively regulated by HNF-3a, -p, or -y  through interaction with the respective 
c/5-acting HNF-3-binding elements in the promoters of these genes. Examples of 
such genes include albumin (Liu et a l, 1991), aldolase B (Gregori et al, 1993), a l -  
antitrypsin (Samadani and Costa, 1996), a2-macroglobulin (Samadani and Costa, 
1996), apoliproprotein B (Brooks et a l, 1991), insulin-like growth-factor binding 
protein 1 (O’Brien et a l, 1995), transthyretin prealbumin (Qian and Costa, 1995) 
and transferrin (Stenson et a l, 2000). In contrast, HNF-3 bound to the HNF-3 
binding site o f the human aldolase B promoter completely antagonizes
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transactivation of the liver-specific aldolase B gene by HNF-1 and DBP (Gregori et 
al, 1993).
Partial hepatectomy produces minimal fluctuation in HNF-3 (a, p and y) and 
transthyretin expression, suggesting that HNF-3a, -p and -y  expression is not 
influenced by proliferative signals induced during liver regeneration. In acute-phase 
livers a dramatic reduction in HNF-3a expression is observed, which correlates with 
a decrease in the expression o f target genes, such as the transthyretin gene (Qian et 
al, 1995).
PINF-3y is an important regulator o f liver-specific genes, and the expression o f this 
factor is reduced in the liver injured by the toxin carbon tetrachloride (CCI4) 
(Nakamura et a l, 1999). HNF-3y is thought to be involved in anterior-posterior 
regionalization o f the primitive gut. In the HNF-3y locus, 170 kb contain all the 
elements important in the regulation of HNF-3y. A 3’-enhancer could be identified 
that contains a H N F-la and ~p-binding site that was shown to be crucial for 
enhancer function in vitro (Hiemisch et al, 1997).
Studies using embryoid bodies in which one or both HNF-3a or HNF-3p genes were 
inactivated showed that HNF-3 P was necessary for expression of HNF-3a. HNF-3 p 
positively regulated the expression of H N F-4a/H N F-la and their downstream 
targets, implicating a role in diabetes. In these studies HNF-3a acted as a negative 
regulator of H NF-4a/HNF-la, demonstrating that HNF-3a and HNF-3P have 
antagonistic transcriptional regulatory functions in vivo. HNF-3 a  did not appear to 
act as a classic biochemical repressor but, rather, exerted its negative effect by 
competing for HNF-3-binding sites with more efficient activator HNF-3 p. In 
addition, the HNF-3a/HNF-3p ratio was modulated by the presence of insulin,
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providing evidence that the HNF network may have important roles in mediating the 
action o f insulin (Duncan et a l, 1998).
1.1.5.1.4. Hepatocyte Nuclear Factor-6 “HNF-6”
The Hepatocyte nuclear factor-6 (HNF-6) is a liver-enriched transcription factor that 
contains a single-cut domain and a novel type o f homeodomain. Comparative trees 
o f mammalian, Drosophila, and C. elegans proteins showed that HNF-6 defines a 
new class o f homeodomain proteins called ‘onecut class’, OC (Lannoy et al., 1998). 
Human OC-2, the second mammalian member o f this class, is located on human 
chromosome 18. The distribution of OC-2 mRNA in humans is tissue-restricted, the 
strongest expression being detected in the liver and skin. The amino acid sequence 
o f OC-2 contains several regions of high similarity to HNF-6. The recognition 
properties o f OC-2 for binding sites present in regulatory regions of liver-expressed 
genes differ from, but overlap with, those o f HNF-6. It might be that in the future, 
HNF-6 and OC-2 will be regarded as two members o f a bigger family (Jacquemin et 
al, 1999).
In 1998, Rastegar and coworkers have identified two rat cDNA species coding for 
two isoforms, HNF-6a (465 residues) and HNF-6(3 (491 residues), which differed 
only by the length o f the spacer between the two DNA binding domains (Rastegar et 
al, 1998). Observation that HNF-6 contributes to the control of the expression of 
transcription factors and is expressed at early stages of liver, pancreas, and neuronal 
differentiation suggest that HNF-6 participates in several developmental programs 
(Landry et a l, 1997).
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HNF-6 recognizes the -138 to -126 regions o f the HNF-3p promoter. Site-directed 
mutagenesis o f this HNF-6 site diminishes reporter gene expression, suggesting that 
HNF-6 activates transcription o f this promoter and may thus play a role in epithelial 
cell differentiation o f gut endoderm via regulation of HNF-3 p (Samadani and Costa, 
1996). Later, it was recognized that HNF-6 is required for HNF-3 p promoter 
activity and that HNF-6 also recognizes the regulatory region of numerous liver- 
specific genes (Rausa et al., 1997).
HNF-6 expression can be regulated by growth hormone (GH) (Lahuna et a l , 2000). 
In hypophysectomized rats, HNF-6 mRNAs increase within 1 h after a single 
injecton o f GH. The same GH-dependent induction could be reproduced on isolated 
rats (Rastegar et al., 2000). It appears that GH stimulates transcription of the HNF-6 
gene by a mechanism involving STAT-5 (signal transducer and activator of 
transcription 5) and HNF-4. Moreover HNF-6 appears to participate not only as an 
effector, but also as a target, to the regulatory network o f liver transcription factors, 
and that several members of this network are GH-regulated (Lahuna et al., 2000). 
Recent studies from Lemaigre and coworkers (1999) reveal that HNF-6 inhibits the 
glucocorticoid-induced stimulation of two genes coding for enzymes of liver glucose 
metabolism, 6-phosphofructo-2-kinase and phosphoenol-pyruvate carboxykinase. 
The authors demonstrated that binding of HNF-6 to DNA is required for inhibition 
of glucocorticoid receptor activity. Furthermore both in vitro and in vivo 
experiments suggest that this inhibition is mediated by a direct HNF- 
6/glucocorticoid receptor interaction involving the amino-terminal domain of HNF-6 
and the DNA-binding domain of the receptor (Pierreux et al., 1999).
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I.I.5 .I.5 . CCAAT/Enhancer Binding Protein
CCAAT/enhancer binding protein (C/EBP) was First discovered in rat liver nuclei 
(Graves et al., 1986). C/EBP proteins are four transcription factors described as 
C/EBPa, C/EBPp, C/EBP8, and C/EBPy. They are highly enriched in the liver but 
they are also found in fat cells (Kel et al., 1995). The composite regulatory elements 
affecting gene transcriptions of C/EBPp are as follows: 
CTGGGAAGATGTTGCTTA. It activates p-fibrogen (p-Fg) and IL-8 in human 
genes, but in the rat it activates the cytochrome-P450 (CYP2D5) gene, and in the 
mouse it activates the serum albumin gene (Kel et al., 2000).
C/EBP belongs to the bZIP family. The bZIP m otif is composed of 50-60 amino- 
acid residues. It consists o f two distinct segments: the leucine zipper and the basic 
region (Landschulz et al., 1989; Kim et al., 1993). The leucine zipper mediates 
dimerization and symmetrically positions a divergent pair o f basic-region a-helices, 
through the major groove of each DNA half-site (Agre et al., 1989).
The basic region (bZIP segment) undergoes a folding transition. The previously 
unfolding basic region becomes a-helical and a quintet o f conserved basic region 
residues are positioned to make contact with the DNA (Ellenberger et al., 1992). 
Generally mutations causing replacement of the leucine residues in the leucine 
zipper prevent the combination o f polypeptide chains to each other, whereas 
mutations in the basic region abolishes binding o f the leucine zipper to DNA 
(Hawkins, 1996). It should be noted that the leucine zipper does not bind directly to 
DNA but it facilitates the dimerization o f the protein. Such dimerization provides 
the correct protein structure for DNA binding, which is enriched in basic amino- 
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Figure 1.10. Model for the structure of the Leucine Zipper and the adjacent DNA- 
binding domain following dimerization of the transcription factor C/EBP (adapted 
from Latchman, 1990).
(Latchman, 1990). bZIP proteins mediate a range of biological processes including 
segmentation, energy regulation, memory and oncogenesis (Cordes et al., 1994).
Both C/EBP(3, and C/EBP8  are implicated in signal transduction as nuclear targets 
for cytokine induced gene expression in various dividing and non-dividing cell 
types.
C/EBPa has been shown to activate glutathione S-transferase genes (GST) in the rat. 
Furthermore, in the non-growing and active metabolizing normal liver, C/EBPa
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expression is high and restricted to hepatocyte-cells. However, in rapidly growing 
hepatoma cells its expression is low (Friedman et al., 1989).
C/EBPa binds to the promoter of the albumin, al-antirypsin, alcohol 
dehydrogenase, and factor IX genes (Flodby et a l , 1993). In partial hepatectomy in 
rats C/EBPa has been shown to have a rapid down regulation at the transcriptional 
level, whereas the C/EBPp, and C/EBP8 are induced (Flodby et al., 1993). 
Furthermore, C/EBP is shown to control ApoB expression (Birkenmeire et al., 
1989).
Rastegar et al., (2000) have shown that in hypophysectomized rats GH treatment 
leads to a rapid decrease in liver C/EBPa protein concentration at the time when 
HNF-6 mRNA is increased by the GH. This is followed by an increase in the 
C/EBPa mRNA and protein at the time when there is a decrease in the level of 
HNF-6 mRNA. The authors have concluded that both C/EBPa mRNA and protein 
levels are controlled by GH.
Studies by Mischoulon et al., (1992) have shown that in partial hepatectomized rats 
C/EBPa mRNA levels decrease by 60-80% within 1-3 hours. It also decreases 
during the growth of freshly isolated normal hepatocytes in culture. The decrease in 
C/EBPa is shown to be blocked by cycloheximide. The drop in C/EBPa gene 
expression suggests that C/EBPa has an anti-proliferative role in highly 
differentiated cells.
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1.2.Liver-Specific Gene Expression-The Example o f  Heme Oxygenase 
(HO)
1.2.1. Definition and Structure of Heme Oxygenase (HO) 
[E.C.1.14.99.3]
The expression o f HO-1 is known to be particularly high in the liver (Maines, 1988) 
In 1968, Tenhunen et al. described the enzymatic conversion o f heme to bilirubin by 
heme oxygenase (HO) using microsome fractions from various tissues, including the 
liver and spleen, it is now clear that the enzyme activity initially detected in the 
liver. Heme oxygenases are microsomal isozymes that catalyze the first and rate- 
limiting step in the degradation of heme. To date, three isoforms have been 
identified i.e. heme oxygenase-1 (HO-1), heme oxygenase-2 (HO-2) and heme 
oxygenase-3 (HO-3) (Maines et al., 1986; McCoubrey et al, 1997).
HO-1 is a 32-kDa protein that is normally synthesized predominantly on the free 
polysomes and then translocated to the endoplasmic reticulum where its 
carboxyl terminal is inserted into the membrane and its amino terminal 
protrudes into the cytoplasm (Shibahara et al., 1980). HO-2 is a 36-kDa protein 
also located in the membrane of the endoplasmic reticulum (McCoubrey et a l ,
1993) existing primarily in the brain and testes. Under physiological conditions,
HO activity is the highest in the spleen where senescent erythrocytes are 
sequestered and destroyed, but its activity has also been observed in all systemic 
organs.
The HO-1 and HO-2 enzymes catalyze the cleavage o f heme in presence of 
NADPH cytochrome P-450, to yield equimolar quantities of biliverdin IXa, 
carbon monoxide (CO) and iron as shown in Figure 1.11. (Maines, 1988;
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Tenhunen et al., 1968). Biliverdin in presence of biliverdin reductase is 
converted to bilirubin. It should be noted that the 33-kDa HO-3 isozyme also 
catalyses heme degradation although with a lower ability to oxidize heme than 


















Figure 1.11. Schematic presentation of heme breakdown by heme-oxygenase.
The active site o f the HO isozymes is believed to be located on the cytoplasmic 
site o f the endoplasmic reticulum (Hino et al., 1979). The catalytic site in HO-1 
and HO-2 shows 100% homology, although overall their amino acid homology 
is only 58% (Maines, 1988). HO-1 is believed to be inducible whereas HO-2 is 
non-inducible. Although HO-1 and HO-2 enzymes have similar function in the 
cells, their size and structure are quite different. Furthermore these 2 isozymes
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are immunologicaly different as shown by the use o f HO-1 anti serum (Maines 
et al., 1986). Thus the two isozymes are thought to be genetically different 
(Curse etal., 1988).
Some o f the main differences between HO-1 and HO-2 are summarized in 
Table 1.1.
T a b le l.l. The physical properties o f HO-1 and HO-2.
Property HO-1 HO-2
Apparent monomeric 
molecular weight on 
SDS gel
32,000 36,000
Heat sensitivity (loss of 








Lower mobility Higher mobility
Requirement for activity 0 2, NADPH, NADPH-Cyt 
P-450 reductase
0 2, NADPH, 
NADPH-Cyt 
P-450 reductase
Km for hematin 0.24pM 0.40pM
Effect of heme ligands (CO, 
KCN, and NaN3)
Inhibition Inhibition







Biliverdin IX Biliverdin IX
Substrate Hematin, Fe-hematoporphyrin, Fe- 
hematoporphyrin acetate, 






cyt P-4506, cyt P- 
420b, cyt P-420c
Specific activity 4000 nmol of bilirubin/mg 
protein/hour
250 nmol of 
bilirubin/mg 
protein/hour
Site of interaction with heme 
molecule
Histidine residue at position 
-132 in human HO-1
Histidine residue at 
position -152 in 
human HO-2
1.2.2. Inducers of the HO-1 Gene
Although heme is the typical HO-1 inducer, several studies demonstrated that HO 
enzyme activity could also be stimulated by a variety of non-heme products. 
Stimulation o f HO-1 expression is regulated primarily at the level o f gene 
transcription (Choi and Alam, 1996). Indeed the rate o f transcription of the HO
32
gene could be enhanced not only by heme but also by a variety of agents including 
oxidants such as hydrogen peroxide (H2O2), ultraviolet A (UVA, 320-380nm) 
radiation, heavy metals, sodium arsenite (NaAS2C>3), thiol scavengers (i.e. 
Glutathione depletion), prostaglandins, endotoxin, cytokines, nitric oxide, phorbol 
esters and 12-O-tetradecanoyl-phorbol- 13-acetate (Keyse and Tyrrell, 1989; Tyrrell 
et al., 1993; Lavrosky et ah, 1993a; Maines, 1988; lu et al, 1997; Lautier et al., 
1992; Elbirt et ah, 1998; Oguro et ah, 1996; Alam and Den, 1992; Rossi and 
Santoro, 1995, Carraway et ah, 1998, Terry et ah, 1998; Doi et ah, 1999 and Maines 
et al., 1986). Also CdCh has been shown to be necessary and sufficient for the HO- 
1 gene activation (Alam et ah, 2000).
In addition HO-1 is induced by drugs, metaloporphyrins, heat shock, shear stress, 
hematin promobenzene and phenyl hydrazine (Wagner et ah, 1997; Otterbein and 
Choi, 2000b). However, it should be noted that the induction o f HO-1 by heat shock 
depends on the cell type. For instance a heat shock produces a great increase of HO- 
1 mRNA in Hep 3B cell line whereas it produces small increase in human fibroblast 
and HepG2 cell line with no increase in Hela cell line, macrophages and 
erythroblastic cells (lu et ah, 1997).
Shan et ah, (2000) demonstrate that the metalo-porphyrins especially Fe- 
protoporphyrin (heme) and Co-protoporphyrin (cobalt) strongly induce the activity 
o f HO-1, and the key elements required for the metaloporphyrins-mediated 
induction o f HO-1 are located at region -3.6 to -5.6 kb upstream of the transcription 
starting point due to the presence o f the consensus AP-1 binding element at regions 
-3647 and -4576.
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1.2.2.1.The Significance of HO-1 Induction
Because o f the growing list o f HO-1 inducers, much effort has been concentrated on 
defining a unifying mechanism to explain the induction o f HO-1 by chemically and 
structurally diverse agents. In 1991, Tyrrell and coworkers noted that many, if  not 
all, HO-1 inducers could promote a cellular pro-oxidant state and that induction o f 
HO-1 represented a general response to oxidant stress (Applegate et al., 1991). The 
authors proposed that cellular oxidative stress, resulting from either increased 
production o f reactive oxygen species or decreased levels of intracellular reductants, 
should be the common effector system for the various HO-1 inducers and that the 
induction o f HO-1 might reflect a powerful mechanism by which the pro-oxidant 
state o f the cells can be transiently lowered in order to avoid damage during a 
sustained oxidative stress. Subsequent studies by multiple investigators have 
confirmed the protective function of HO-1 induction and activity during injury 
initiated by both heme and non-heme insults. In the light o f such studies, it was 
assumed that the cellular disruption by non-heme toxicants should also promotes the 
release of, or access to, sufficient amounts o f substrate for the induction of the HO-1 
enzyme (Choi and Alam, 1996).
Although HO-1 is still known to catalyze only one enzymatic reaction (i.e. the 
oxidative cleavage of heme) new investigations in the field suggest that the cellular 
and physiological consequences of this reaction are considerably more significant 
since HO-1 appears to function as a cytoprotective molecule. Indeed, because o f 
this reaction, HO-1 manifests antioxidant, anti-inflammatory and anti-apoptotic 
activities, modulates inter- and intracellular signaling mechanisms, and ultimately 
participates in the more general process of cellular homeostasis in response to injury 
(Alam, 2002).
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The mechanism(s) by which HO-1 can mediate these cytoprotective functions is not 
clear. However the three major catalytic by-products, CO, ferritin, and bilirubin 
may represent potential targets:
• C arbon monoxide, CO, is unquestionably dangerous for the organism, as it 
can bind avidly to hemoglobin and replace oxygen (O2), can induce general 
hypoxia, increase the stability o f oxyhemoglobin by shifting the dissociation 
curve to the left and impede O2 delivery to the tissues. Furthermore, the 
consequent impaired dissociation of carbon dioxide (CO2) can lead to an 
increase in blood CO2 levels and to the removal o f the reflex stimulus to the 
respiratory centers in the brain (Otterbein and Choi, 2000b).
At high concentrations CO is lethal but recent studies in the field o f neuro- 
and vascular biology consistently support the idea that CO at low 
concentrations exerts distinctly different effects on physiological and cellular 
functions (Mancuso et a l , 1997; Motterlini et al., 1998; Verma et a l , 1993). 
To this regard it has been shown that CO generated from HO, the primary if 
not exclusive source o f CO generation in the body, can regulate vasomotor 
tone (i.e. as a vasorelaxator) as well as neurotransmission (Snyder et a l, 
1998; Morita and Kourembanas, 1995). A recent study from Nadel and 
coworkers (1998) clearly demonstrates that such effects o f CO are mediated 
through the activation of guanylyl cyclase on the binding o f CO to the heme 
moiety o f this enzyme and subsequent cyclic guanine monophosphate 
(cGMP) generation (Cardell et a l, 1998). It is thought that CO may also 
possess anti-inflammatory effects such as the capacity to inhibit platelet 
activation or aggregation through activation of guanylyl cyclase and the 
subsequent generation of cGMP. Moreover, in models o f lung injury,
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administration o f very low concentrations of exogenous CO to rats and mice 
had protective effects (Otterbein et al., 1995 and 2000a). Changes in CO 
measurements in exhaled breath have been recently suggested as a direct 
indicative o f increased HO-1 activity and cellular stress and therefore as a 
direct diagnostic marker of the severity o f some o f the disease processes such 
as asthma and diabetes (Paredi et al., 1999; Yamara et al., 1999).
• Bilirubin is best known as potentially toxic agent that accumulates in the 
serum of neonates, causing jaundice. However this byproduct o f HO, which 
was originally considered as only a waste product of enzymatic cleavage o f 
heme to be eliminated, is now considered as the most abundant endogenous 
antioxidant in mammalian tissues. Ames and coworkers (1987) were among 
the first investigators to discover that both biliverdin and bilirubin possess 
potent antioxidant activities such as scavenging peroxyl radicals as 
efficiently as vitamin E (Stocker et a l, 1987; Stocker et al., 1990). Rice- 
Evans and coworkers (1994) further demonstrated that bilirubin account for 
the majority of the antioxidant activity o f human serum (Gopinathan et al.,
1994). HO-derived bilirubin has also been shown to be protective against 
both postischemic myocardial dysfunction (Clark et al., 2000) and H2O2- 
mediated injury to neurons (Dore et a l , 1999). In a recent report, 
Vachharajani et al., (2000) have shown that administration o f biliverdin to 
rats modulates lipopolysaccharide-induced P- and E-selectin expression in 
the vascular system, providing evidence that bilirubin is able to modulate 
this inflammatory response regardless of the influences o f HO-1, CO and/or 
ferritin. The authors further demonstrated that biliverdin administration also 
provides protection in a rat model o f ischemic heart injury.
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• Ferritin  is a major iron storage protein in the cells. The release of 
potentially harmful free iron capable of generating hydroxyl radical through 
Fenton chemistry with the superoxide radical is rapidly sequestered into 
ferritin. This is thought to lower the pro-oxidant state of the cell by 
removing the free iron (Balia et al., 1992). In (1993), Vile and Tyrrell 
showed that ferritin levels increase in the presence of UVA-mediated 
oxidative stress in human skin cells. The authors further demonstrated that 
HO-1-dependent release o f iron also results in the upregulation of ferritin, 
which might provide protection after irradiation. Eisenstein et al, (1991) 
clearly showed that ferritin is increased in tandem with HO-1 and decreased 
with inhibition in HO-activity. Balia et al, (1992) also showed that 
induction o f ferritin was cytoprotective in a model o f oxidant stress, 
demonstrating that cytotoxicity was greatly reduced and occurred 
independently o f HO-1 activity. Finally, Otterbein et al (1997) in a model 
o f endotoxic shock, demonstrated that when iron is chelated by the 
exogenous iron chelator desferrioxamine, no ferritin is induced and 
protection is ablated. From these studies a picture emerged showing that the 
HO-mediated iron release plays a role in increasing the intracellular level of 
ferritin which in turn protect the cells against further oxidative injuries.
1.2.3. Other Functions of HO-1
Although the by-products o f heme cleavage play a significant role in the 
cytoprotective role attributed to HO-1, it is now more and more clear that the 
induction/ activity o f this enzyme results in profound changes in cells’ abilities to
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protect themselves against oxidative injury. As mentioned previously, HO-1 has 
been shown to have anti-inflammatory, antiapoptotic and antiproliferative effects. 
Furthermore this enzyme appears to have salutary effects in diseases as diverse as 
atherosclerosis and sepsis (Morse and Choi, 2002).
Observations made in HO-1-deficient [HO-1 (-/-)] mouse and human have 
highlighted the important metabolic and cytoprotective roles of this gene. For 
example Poss and Tonegawa (1997a and 1997b) generated HO-l(-/-) mice by 
targeted deletion o f the mouse HO-1 gene. The mice exhibited incapacity to 
modulate body iron stores properly and were less resistant to hepatic injury by iron, 
indicating that HO-1 plays an important role in iron utilization. The authors 
reported that the majority o f these HO-l(-/-) do not survive to term, and the mice 
that do survive to adulthood are abnormal and die within one year o f birth.
A recent report (Yachie et al., 1999) demonstrating the first identified case o f a HO- 
1-deficient human patient lends additional support to the evolving paradigm that 
HO-1 serves to provide cytoprotection against oxidative stress. This patient 
exhibited phenotypic alterations as those observed in the HO-l(-/-) mice, including 
growth retardation, anemia, leukocytosis and increased sensitivity to oxidative 
stress.
The critical importance o f HO is also demonstrated by reports (Lee, 1995; 
Muramoto et al., 1999) that HO expression is conserved evolutionarily in 
prokaryotic bacteria as well as in plants and fungi. This conservation suggests that 
HO may play a role in diverse species as a modulator of cellular homeostasis, 
serving not only to degrade heme but also, via one or more of its catabolic by­
products, to regulate a variety of critical cellular processes. For example, in plants, 
it is believed that HO possesses dual functions, one that generates tetrapyrroles and
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another that recycles heme and chlorophylls, both being important after damage to 
the photoreactive center (Muramoto et al., 1999). In most bacteria, iron is required 
for survival and it is particularly essential for pathogens to cause disease. To 
circumvent the low concentration o f free extracellular iron, pathogenic bacteria have 
developed sophisticated mechanisms by which to acquire iron from iron-containing 
proteins found in their hosts. One such mechanism exploits a bacterial heme 
degradation enzyme similar to HO (Lee, 1995).
HO-1 plays also a crucial role in cardio-protection as it can partially rescue the heart 
from the ischemia/reperfusion injury by functioning both as an intracellular 
antioxidant and inducer of its own expression under stressful conditions such as 
preconditioning, that provokes oxidative stress and induces a large variety of 
oxidative stress-inducible gene (Yoshida et al., 2001).
In addition expression of HO-1 is essential to prevent graft rejection presumably due 
to the generation o f CO that prevents thrombosis and infraction of graft rejection 
(Sato et al., 2001).
Furthermore, HO is believed to be involved in the regulation of vascular tone and 
blood pressure (Sabaawy et al., 2001). And finally with regard to heme degradation, 
the activity o f the enzyme seemed to be higher in tissues involved in the breakdown 
o f red cells e.g.: spleen, bone marrow, and liver (Tenhunen et al, 1970; Shibahara et 
a l , 1978).
1.2.4. Inhibitors of HO
Some substances, which inhibit HO, include CO, KCN, NaN3, (Levere et al., 1990; 
Sacerdoti et al., 1989; Martasek et al., 1991), and certain non-physiological 
metalloporphyrins such as Tinprotoporphyrin (Kappas et al., 1984),
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Znprotoporphyrin (Maines, 1981), and Cr- and Mn- protoporphyrin (Kappas et al.,
1984), inhibit the heme degradation activity by interacting with the heme binding 
site of HO protein.
1.2.5. Mouse Heme Oxygenase-1 Gene
The mouse HO-1 gene is approximately 7 kb in length, is organized into five exons 
interrupted by four introns as shown in Figure 1.12. The deduced amino acid 
sequence o f the mouse HO-1 gene exhibits 93.4%, 82.3%, and 64.4% identity with 
the rat (Benton et al, 1977), human (Yoshida et al, 1988), and chicken (Evans et 
al, 1991) proteins, respectively. Simultaneous alignment o f all four sequences 
using the algorithm o f Higgins and Sharp (1988) showed 57.4 % sequence identity.
In addition, the histidine residue (at positions 25 and 132 of the rat sequence) 
proposed (Evans et a l , 1991; Ishikawa et al., 1992) to bind the substrate heme to 
the active center o f the enzyme is conserved in the mouse protein. The 
transcription initiation site was identified by SI endonuclease mapping (SI) and 
primer extension (PE) analyses represented at position +1 (Alam et al, 1994).
E c o m + l EcoRA Xhol Bam HI Hindlll
4-tjJ— i— iia--- Li— tn -
EXON 1 E X O N 2 E X O N 3 E X O N 4 EXON 5
Figure 1.12. Partial restriction map and structural organization of the mouse HO-1 
gene, the position o f the exons are marked by open boxes (untranslating region) and 
solid boxes (protein coding region).
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1.2.5.1. Mouse Heme Oxygenase-1 Upstream Promoter Elements 
In 1992, Alam et al. demonstrated that the basal expression of a chimeric gene 
consisting o f approximately 7 kb of the 5’-flanking region of the mouse HO-1 gene 
fused to the bacterial chloramphenicol acetyltransferase (CAT) reporter gene was 
two to ten fold greater o f an analogous construct containing only 1287 bp of the 5’- 
flanking region in transiently transfected cultured cells. The authors localized this 
enhancer activity to a 268 bp fragment positioned approximately 4 kb upstream of 
thfe transcription initiation site. Using the Dnase I protection assay, they further 
demonstrated that this fragment called “SX2” contained two high affinity protein 
binding sites i.e. region A (TGAGTCA) and region B (TGTGTCA) that resembled 
the consensus binding site, TGA(G/C)TCA, of the activator protein-1 (AP-1) family 
o f transcriptions factors. Further functional studies revealed that indeed the SX2 
region, which mediates basal level and inducer-dependent activation o f mouse HO- 
1 gene, contains two functional AP-1 binding sites (i.e. AP-1 a and AP-lb) and that 
mutation o f both o f these elements diminishes (by 50-70%), but does not abolish 
the enhancer activity, suggesting that other sequences should contribute to enhancer 
function o f the 5’-flanking region of the mouse HO-1 gene. In (1994), Alam 
showed that directly upstream of these AP-1 binding sites are two copies o f a 
sequence motif, which resembles elements found in cellular and viral genes that are 
known to interact with the C/EBP protein family o f transcription factors. These 
SX2 sequences bind specifically to liver-enriched, heat-stable nuclear proteins and 
confer C/EBPa-dependent transactivation of the heterologous CAT gene. Further 
mutational analyses indicated that both the AP-1 and C/EBP binding elements are 
required for optimal activation of the mouse HO-1 gene by cadmium and other 
metals. Since multiple copies of the AP-1 binding elements, but not C/EBP
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elements, are necessary and sufficient for activation o f a heterologous gene by 
CdCb, the AP-1 proteins appeared to play the primary role in the activation process 
(Alam, 1994). The same year Shibahara and coworkers (Takeda et a l , 1994) 
isolated the human homolog o f the SX2 region and in contrast to the mouse studies 
by Alam (1994), their studies indicated that the AP-1 elements do not mediate 
induction o f a heterologous gene in response to cadmium.
Using transient expression assays with CAT reporter gene and deletion analysis 
within the 5’-flanking region o f the mouse HO-1 gene, Alam et al, (1994) further 
demonstrated that the basal promoter activity in several cell lines (i.e. fibroblast 
L929, rat C6 glioma and rat hepatoma cells) is located within 149 bp o f the 
upstream sequence. This proximal promoter region o f the mouse HO-1 gene 
contains several sequence elements that are not only conserved in both the rat and 
human HO-1 genes but also resembles consensus binding sites of various 
transcription factors including AP-1, AP-4, C/EBP and c-Myc:Max/USF.
The DNA sequences upstream of the transcription initiation site o f the mouse and 
rat HO-1 genes (Muller et a l, 1987) are highly conserved, with the notable 
exception o f an insertion o f polypyrimidine tract, comprised mainly of the repeated 
pentamer TCTCT, in the mouse gene. These homopurine/homopyrimidine 
polymorphic sequences, possessing Z-conformation potential, have been shown to 
negatively affect transcriptional activity of genes such as the rat prolactin (Naylor 
and Clark, 1990). These alternating repeats are present in the promoter regions of 
several genes including the human c-Ki-ras proto-oncogene (Hoffman et a l , 1990) 
and the human HO-1 gene (Kimpara et al, 1997). Excluding the polypyrimidine 
tract, the mouse and rat HO-1 gene 5’-fanking regions exhibit 86% sequence 
similarity (Alam et a l , 1994).
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The mouse HO-1 gene 5’-flanking region also contains three heat shock elements 
(HSEs), one o f which is analogous to the rat HSE motif, called HSEa (Muller et al, 
1987; Alam et a l, 1994). However, none of these putative HSEs, contain the three 
intact GAA/TTC blocks, which may explain the weak response of the mouse HO-1 
to hyperthermia (Alam et a l, 1989). On the other hand, the human HO-1 gene 
promoter contains such intact HSE, but is unresponsive or only minimally 
responsive to hyperthermia in several cell lines (Shibahara et a l, 1989; Mitani et 
al, 1990).
Heavy metals activate HO-1 gene transcription and the rat gene contains a putative 
metal regulatory element, MRE (Muller et a l, 1987), that is completely conserved 
in the mouse gene. However, transient expression analyses performed by Alam et 
al, (1994), indicated that this sequence containing core heptanucleotide 
‘TGCACTC’ identical to that o f the strongest MRE of the mouse metallothionein 
gene was not responsive to cadmium or zinc. To identify the specific regions 
within the 5’-distal sequence of mouse HO-1 gene responsible for its induction by 
both heme and heavy metals, the authors stably transfected several constructs 
containing either the entire mouse HO-1 gene or various portions of the 5’-flanking 
region into rat C6 glioma cells. The simultaneous and quantitative analysis o f the 
mouse and rat HO-1 mRNAs indicated that the distal 5’-sequences, between 
positions -3.5 and -12.5 kb, were required for induction of mouse HO-1 gene 
transcription.
To this regard, in (1995), Alam et al, described a second regulatory region called, 
AB1 (161 bp), located approximately 10 kb upstream of the mouse HO-1 gene with 
properties similar to SX2. The authors further demonstrated that this fragment 
contains three copies of the AP-1 binding sequence and mutation o f these elements
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abolishes induction not only by CdCh, but also by heme and a variety o f other HO- 
1 inducers. These results demonstrated for the first time that the mechanism of HO- 
1 gene activation by diverse agents converges at the same DNA m otif and provided 
further evidence for the importance o f Fos/Jun proteins in this process. The 
signaling pathway leading to the expression and/or activation o f the transcription 
factors, however appeared to be inducer-dependent. For example Inamdar et al, 
(1996) showed that the AP-1 binding sequence, TGAGTCA, is necessary but 
insufficient for gene activation by heme or cadmium. Furthermore the authors 
reported that the five AP-1 motifs o f the SX2 and AB1 enhancers exhibit sequence 
similarity beyond the AP-1 heptad and that the heme response element (FIRE) is 
actually an extended AP-1 binding sequence, i.e. (T/C)GCTGAGTCA. This motif 
resembles the binding site of the product o f the v-M af oncogene (Kataoka et a l ,
1994) and o f the transcription factor nuclear factor-erythroid 2, NF-E2 (Andrews et 
a l , 1993a; Andrews et al, 1993b). The HRE is in fact a composite element that 
also contains overlapping sequences for the antioxidant responsive element, ARE,
i.e. GCnnnGTCA (Rushmore et a l , 1991) and the AP-1 heptad. The ARE is a 
transcriptional regulatory element that plays a role in the expression of phase II 
enzymes such as Glutathione-S-transferase and NAD(P)H:quinone oxidoreductase 
(Rushmore et a l , 1991; Xie et a l , 1995; Wasserman and Fahl, 1997).
The composite HRE/AP-1/ARE cA-acting elements present in several copies within 
the mouse HO-1 enhancer regions are now generally termed as the stress response 
elements, StREs (Choi and Alam, 1996) that are essential for inducer-dependent 
gene activation. The consensus StRE is defined as (T/C)GCTGAGTCA, and as 
mentioned above, it does resemble the consensus binding site, TGA(C/G)TCA, for 
the AP-1 class o f transcription factors that have been proposed to be responsible for
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HO-1 gene activation (Alam and Den, 1992; Alam J., 1994). These predictions 
were based, among other reasons, on the observations that AP-1 proteins bind to 
individual StREs, that the DNA binding o f c-Jun.c-Fos heterodimer is subjected to 
redox regulation, and that expression and activities o f some members of the Jun and 
Fos family of proteins are stimulated by many of the same agents that induce HO-1 
expression (Alam et a l, 1999). A role for AP-1 proteins in HO-1 gene regulation is 
further supported by recent studies demonstrating that pharmacological inhibition 
of AP-1 activity attenuates interleukin-la or tumor necrosis factor-a-mediated 
induction of HO-1 mRNA levels in human endothelial cells (Terry et al, 1998) and 
ectopic expression of a dominant-negative mutant o f c-Jun inhibits arsenite- 
mediated activation o f the chicken HO-1 promoter in hepatoma cells (Elbirt et al, 
1998). Also, in (1995), Camhi et al, showed that lipopolysaccharide (LPS)- 
induced HO-1 gene transcription in RAW264.7 macrophages is mediated by the 
distal enhancer SX2. Further deletion analyses from the same laboratory 
demonstrated that the transcription factor AP-1 is critical for AB1-mediated HO-1 
gene activation by LPS (Camhi et a l, 1998). Their data suggested that LPS 
regulates HO-1 gene transcription in part by inducing the production of reactive 
oxygen species, which initiate signal transduction pathway(s) leading to the 
activation of AP-1-dependent HO-1 gene transcription.
1.2.6. Human Heme Oxygenase-1 Gene
The human HO-1 gene coding sequence is about 14 kb long and organized into five 
exons and four introns as shown in Figure 1.13.
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Figure 1.13. Restriction map and structural organization o f the human HO-1 
gene, the position of the exons are marked by open boxes (untranslating 
region) and solid boxes (protein coding region).
The transcription initiation site was identified by SI nuclease mapping and primer- 
extension analysis. The size o f the major primer cDNA was about 80 nucleotides 
indicating the transcription initiation site located upstream from the Hpall site. The 
SI probe located from position -99  to +70 labeled at the Banll site as shown in 
Figure 1.14. (Shibahara et al., 1989).
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- 1 8 0  ATGGCCAGACTTTGTTTCCCAAGGGTCATATGACTGCTCCTCTCCACCCCACACTGGCCC
- 1 2 0  GGGGCGGGCTGGGCGCGGGCCCTGCGGGTGTTGCAACGCCCGGCCAGAAAGTGGGCATCA
Banff
- 6 0  GCTGTTCCGCCTGGCCCACGTGACCCGCCGAGCATAAATGTGACCGGCCGCGGCTCCGGC 
1 
61
Figure 1.14. Nucleotide sequence o f the 5’-flanking region and exon 1 of the 
human HO-1 gene adapted from Shibahara et a l (1989). The transcription 
initiation site is marked with an asterisk. A TATA-like sequence is indicated by a 
thin overline. The ATG codon for initiating methionine is indicated by a thick 
overline. Thin underlines indicate the nucleotide residues which are aligned to the 
same nucleotides of the rat HO gene (Muller et a l , 1987).
1.2.6.1. Human Heme Oxygenase-1 Upstream Promoter Elements 
The upstream element o f the HO promoter is essential for constitutive activity o f 
the HO promoter (Sato et al., 1990). The cis-acting element within 120 bp o f the 
mRNA cap site is involved in the inducible stimulation o f transcription by a variety 
o f agents including oxidants (Tyrrell et al., 1993).
*  •  •  •
AGTCAACGCCTGCCTCCTCTCGAGCGTCCTCAGCGCAGCCGCCGCCCGCGGAGCCAGCAC
1------------------------------ Xho! E x o n  1------------------------------------------
GAACGAGCCCAGCACCGGCCGGAT^GAGCGTCCGCAACCCGACAGGCAAGCGCGGGGC
----------------------—— —--------------------------------------- — 1 Intron 1
Ban II H pall
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One o f the mechanisms by which hormones, growth factors, and other stimuli 
induce the expression o f genes is by activating various transcription factors. These 
processes may be part o f the mechanism by which the agents, including heme, 
increases HO expression and activity (Quan, et al, 2002).
Using DNase I foot print assays, Lavrovsky et a l  (1994) demonstrated the presence 
of NF-kB, HSE and AP-2 binding sites in the proximal part o f the promoter region 
of the human HO-1 as shown in Figure 1.15.
NFkB TATA
ISO -130
-390 CCCAQCTTTC TGfiAACCTTC TGGGACGCCT GGGGTGCATC
-390 AAGTCCCAAG GGGACAGGGA GCAGAAGGGG GGGCTCTGGA
-310 AGGAGCAAAA TCACACCCAG AGCCTGCAGC TTCTCAGATT
-270 TCCTTAAAGG TTTTGTGTGT GTGTGTGTGT GTGTGTGTGT
-230 GTGTATGTGT GTGTGTGTGT GTGTGTGTGT GTGTTTTCTC
NFkB
-190 TAAAAGTCCT ATGGCCAGAC TTTGTTTCCC AAGGGTCATA
A P -2
-150 TGACTGCTCC TCTCCACCCC ACACTGGCCC GGGGCGGGCT
-110 GGGCQCGGGC CCTGCGOQTO TTGCAACGCC
♦  110
Figure 1.15. Schematic representation o f the human HO-1 proximal promoter 
region containing the HSE, NF-kB and AP-2 binding sites and the ATG initiation 
codon (adapted from Lavrovsky et al., 1994)
The authors observed that the most pronounced effect o f heme is on NF-kB and AP- 
2 binding activities and since the activation of NF-kB and AP-2 is often associated 
with the immediate response of the cell to an injury, they suggested that the presence 
o f these regulatory sequences upstream of HO-1 is an strong indicator o f the defense
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mechanism activity of HO-1 against tissue injury (Lavrovsky et al., 1994). A brief 
description o f these transcription factor binding sites is provided below:
>  AP2 is a transcription factor binding site that has been identified in the 
enhancer regions of viral and cellular genes, including simian virus SV40, 
human metallothionein IIA, and human T-cell leukemia virus type I 
(Haslinger et al., 1985; Williams et al., 1988). Phorbolesters, cAMP and 
retinoic acid can induce the AP-2 activity, whose activation is associated 
with the immediate response o f the cell to an injury (Imagawa et al., 1987; 
Snape et al., 1991). Using the computer analysis, Lavrovsky et al.,. (1993a) 
indicated the presence of two AP-2 like regulatory site in the upstream 
region, one having the binding site from position “-116 to -124” with the 
consensus sequence GCCCGGGGC and the second one from position “-7 to 
-1 5 ” with the sequence of GGCCGCGGC. The authors used the Dnase I 
footprint assay to confirm the presence of AP-2 binding sites within the 
human HO-1 promoter. It appears that these binding site play an important 
role in the induction o f HO gene during inflammatory and oxidation stress.
>  NF-kB is a transcription factor that is activated in many different cell types 
by a challenge from primary and secondary pathogenic stimuli. This 
activation leads to a rapid induction o f genes encoding defense and signaling 
proteins (Nolan et al., 1993). NF-kB contains two binding sites from which 
one is transcriptional site AAGTCCCAAG “-370 to -379bp” as found to 
share the same site with the heat shock responsive element (HSE) at the 
5'flanking region (Lavrovsky et al, 1993a; Faisst et al, 1992; Shibahara et 
a l , 1989). The second one was found at position "-156 to -166” bp and its
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sequence is GCTCCTCTCCA. The Dnase I footprint assay confirmed the 
presence o f these NF-kB binding sites within the human HO-1 promoter 
(Lavrovsky et al, 1993a). Carbon monoxide (CO) generated by HO-1 
during heme catabolism is also dependent on the activation of NF-kB 
transcription factor in endothelial cells. This is thought to protect the 
endothelial cells from undergoing tumor necrosis factor-a-mediated 
apoptosis by exerting an anti-apoptotic effect (Brouard et al., 2002).
In addition to these czs-regulatory elements within the 5’-flanking region o f the 
human HO-1 gene, Sato et al, (1990) have identified the upstream stimulatory 
factor (USF) binding site as CACGTGACCCG located 34 bp upstream from the 
transcription initiation site o f the HO-1 gene. The authors provided data suggesting 
that USF contributes to the transcription o f the human HO-1 gene.
In 1994, Shibahara and coworkers (Takeda et a l , 1994) performed transient 
expression assays in four human cell lines including Hela to analyze the cadmium 
mediated inducibility o f the fusion genes containing the firefly luciferase gene as a 
reporter under the control o f the human HO-1 gene promoter. Their results revealed 
that the region between 4.5 and 4 kb upstream from the transcriptional initiation site 
is responsible for cadmium-mediated inducibility on the fusion gene. Further 
functional analyses in Hela allowed limiting the localization o f the cadmium
I ^
responsive element (Cd RE) to 20 bp. The bandshift assays demonstrated that this 
20 bp element is specifically bound by nuclear protein(s) of Hela cells although 
these binding activities were unchanged by the treatment with cadmium. Finally, 
using the synthetic oligonucleotides that had various base changes, the authors 
identified a 10 bp sequence, TGCTAGATTT, required for the cadmium inducibility
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and in vitro protein binding. The following year, the same group (Takeda et al.,
1995) showed by transient expression assays that Cd RE o f the human HO-1 gene 
is not responsive to zinc, whereas a metal regulatory element (MRE) o f the human 
metallothionein IIA gene is able to respond to either cadmium or zinc. The 
consensus sequence of the Cd RE is different from that of the MREs of the mouse 
metallothionein I promoter, TGCRCNC (R, purine; N, any nucleotides) (Stuart et 
al., 1985), except for the TGC trinucleotides as its 5’-end. Takeda et al (1995)
I ^
further demonstrated that the Cd RE is recognized by a certain nuclear proteins 
which is however unable to bind to an MRE o f the metalllothionein IIA gene, 
suggesting that the metal-selective activation o f each gene promoter is mediated by a 
separate mechanism. This is in agreement with the notion that living organisms 
have acquired the two independent systems involved in detoxification of heavy 
metals during evolution.
In (1996), Lavrovsky et a l , examined several human HO-1 promoter-driven CAT 
constructs to analyse promoter activity o f the human HO-1 gene in micro vessel 
endothelial cells. The HO-promoter activity was upregulated by IL6 and 
downregulated by glucocorticoids. The reporter CAT assays revealed that the 
promoter region (56 bp) between -180 and -120 was responsible for upregulation by 
growth factors, as well as for glucocorticoid-directed downregulation. This region 
had a high homology to sequences in the human platelet glycoprotein lib. The 
analysis of DNA-protein complexes revealed that the DNA fragment contains a 
sequence recognized by the STAT3/acute phase response factor.
The (GT)n dinucleotide repeat in the 5’ flanking region o f the human HO-1 gene 
shows length polymorphism and could modulate the level o f gene transcription 
(Kimpara et al., 1997; Exner et al., 2001). Recent evidence from the literature has
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linked the large size of a (GT)n repeats present within the HO-1 gene promoter to 
reduced inducibility of the gene (Exner et al., 2001; Yamada et al., 2000; McGinnis 
et al., 1995). For example the study from Yamada and coworkers (2000) suggest 
that the expression of the HO-1 gene could be altered according to the number of 
(GT)n repeats and that this microsatellite polymorphism may be associated with the 
development of oxidative stress-inducing diseases (Yamada et al., 2000). Using a 
population o f 100 smokers with or without the chronic pulmonary emphysema 
(CPE), the authors grouped the polymorphisms o f the (GT)n repeat into three 
classes: class S allele (<25 repeats), class M allele (25-29 repeats ), and class L 
allele (> 30  repeats). They found that the basal luciferase activity was significantly 
higher in cells transfected with a (GT)2o repeat than in those with either (GT)2 9
(GT)38.
It is also suggested that the poly GT sequences present in the HO-1 gene promoter 
is highly polymorphic due to the location o f the (GT)n repeat between the putative 
heat-shock elements (HSE) and the c/s-regulatory element (MTE) as shown in 
Figure 1.16. (Okinaga etal., 1996).
HSE M TE
(GT)n Exonl
Figure 1.16. Structural organization of the (GT)n repeats in the human HO-1 gene.
In (1997), Lu et al, reported a negative regulatory region in the human HO-1 gene. 
They demonstrated that the basal promoter activity o f the luciferase reporter gene
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which is regulated by the -1416 bp upstream region of the human HO-1 gene was 
lower than that by the -121 bp upstream region o f the gene when both reporter 
constructs were transfected in primary cultures o f chick embryo liver cells.
In (1999), Takahashi et al, assessed approximately 4 kb o f the 5’-flanking region of 
the human HO-1 gene for basal promoter activity and sequenced approximately 2 kb 
of the 5’-flanking region. Basal level expression o f a series o f deletion mutants of 
the 5’-flanking region linked to the luciferase was tested in two human cell lines of 
HepG2 (human hepatoma cells) and Hela (human cervical cancer cells). The 
authors found a positive regulatory region at position -1976 to -1655 bp that 
functioned in HepG2 cells but not in Hela cells. A negative regulatory region was 
also found at position -981 to -412 bp that functioned in both HepG2 cells and Hela 
cells.
To elucidate further the regulation o f the human HO-1 gene expression and to gain 
insight into its tissue preferential expression, in the present study the 4.7 kb of the 
5’-flanking region of the human HO-1 gene was examined for basal promoter 
activity in both HepG2 and Hela cells using a series o f deletion mutant constructs 
linked to the luciferase gene.
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1.3. Aim of the Work
To design new plasiriid DNA expression vectors o f liver-specific gene for the 
purpose o f targeted gene delivery.
1.3.1. Objectives
1. The identification o f liver-specific cis-acting regulatory elements.
2. Design o f synthetic promoters/enhancers containing the candidate liver 
specific c/s-acting elements.
3. The use o f the above elements to drive the expression o f luciferase gene in a 
EBV-based reporter vectors transiently transfected into both liver-specific 
HepG2 and non-liver HtTA-1 cell lines.
4. To analyze the c/s-acting elements within the promoter o f HO-1 gene that is 
known to be highly expressed in the liver.
5. To use EBV-based constructs containing 4.7 kb upstream 5’-flanking region 
o f HO-1 gene in transient transfection assays within two cell lines o f liver- 
specific HepG2 and non liver HtTA-1.
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CHAPTER 2 Materials and Methods
A. Plasmid Constructions 
A.I. Molecular Biology Materials
All biochemicals were analytical grade and purchased from Sigma Chemicals, UK, 
the DNA ladder was obtained from (Fermentas MBI, UK), and all o f the restriction 
enzymes were obtained from (GIBCO, UK) except where indicated.
A.1.1. Antibiotics
Ampicillin (sodium salt) was prepared as a 100 mg/ml solution in water and filter 
sterilized using a 0.2 pm pore membrane (Millpore, UK) and stored at -20°C for up 
to 3 months. Working concentration used was 100 pg/ml.
A. 1.2. Cell Resuspension Solution
50 mM Tris-Hcl (pH 7.5), 10 mM EDTA, 100 pg RNase.
A.1.3. Cell Lysis Solution
0.2 M NaOH, 1% SDS.
A.I.4. Neutralisation Solution
1.32 M potassium acetate (pH 4.8).
55
A.1.5. TE Buffer
Ten mM Tris, 1 mM EDTA, (pH 8).
A.1.6. Ethidium Bromide
Ten mg/ml, 0.2 gm of ethidium bromide resuspended in 20 ml o f H2O, and stored in 
dark.
A.1.7. TAE Buffer
0.04 mM Tris-Acetate, 0.001 mM EDTA.
A.1.8. TBE Buffer (GIBCO, UK)
10 X TBE buffer is a solution o f 1 M Tris, 0.9 M boric acid, and 0.01 M EDTA. 
A.1.9. LB Agar
Bacto-Tryptone 10 g/1
Bacto-yeast extract 5 g/1
Sodium chloride 5 g/1
Reagents for preparing LB were obtained from (Difco, UK). Solutions were 
sterilised by autoclaving at 121°C for 20 minutes.
A. 1.10. Lysis Buffer (Promega, UK)
(1 x :25 mM Tris-phosphate, pH 7.8: 2 mM DTT; 1,2-diaminocyclohexane- 
N,N,N,N-tetraacetic acid; 10 % glycerol; 1 % Triton X-100 and BSA 1 mg/ml).
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A.1.11. Preparation of Tfb I Buffer as in Table 2.1. 
Table 2.1:
Com ponent Q uantity Final concentration
KC1 0.223 g 30 mM
RbCl 1.209 g 100 mM
CaCl2 O .llO g 10 mM
MnCl2
\
0.985 g 50 mM
(% V/V) Glycerol 15 ml 15%
Water To 100ml.
Adjusted to pH 5.8 with 0.2 M acetic acid and filter-sterilized (0.2 pm).
A.I.12. Preparation of Tfb II Buffer as in Table 2.2. 
Table 2.2.
Com ponent Q uantity Final concentration
MOPS 0.209 g 10 mM
CaCl2 0.831 g 75 mM
RbCl 0.121 g 10 mM
(% v/v) Glycerol 15 ml 15%
Water To 100 ml
Adjusted to pH 6.6 with 1 M KOH and filter-sterilized (0.2 pm).
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2.1. Molecular Biology Methods
p706/HO4.7 Plasmid
The majority of the experiments described in this thesis were carried out either with 
the p706 /H04.7 plasmid (16 kb) or its derivatives (see section 5.1.), all kind gifts 
from the laboratory o f Professor R. M. Tyrrell (Pharmacy and Pharmacology 
Department).
In addition to these plasmids, several novel constructs were also made during this 
project based mostly on the modification o f either the promoter or enhancer 
elements o f the p706 plasmids (see section 5.2.).
The p706/HO4.7 contains the 4.7 kb o f the proximal promoter region o f the HO-1 
and was originally constructed to identify the key elements o f the HO-1 promoter 
responsible for the transcriptional activation o f HO-1 by ultraviolet A radiation. 
p706/HO4.7 vector is constructed from a combination o f three-linearised plasmids 
p701 Clal/Kpnl, p629 Clal/BamHI and p653 Kpnl/BamHl, as shown in M ap 1.
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M apl: p706/HO4.7
p706 itself is an Epstein Barr Virus (EBV-based episomal vector) derived from the 
basic episomal plasmid p629 [205MT (ID) poly CAT], originally obtained from M. 
R. James (Human Polymorphism study center, Paris). The Clal/BamHI and the 
Clal/Kpnl fragments of p629 (called p701) were recombined with the KpnI/BamHI 
fragment of pGL2 basic (called p653) to generate p706.
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(1) p701 Clal/Kpnl fragment: This fragment contains the latent origin of 
replication (oriP), and Epstein Barr Nuclear Antigen-1 (EBNA-1) sequences o f the 
EBV-based vector p629.
(2) p629 Clal/BamHI fragment: This fragment contains both hygromycin- and 
ampicillin-resistance genes o f the EBV-based vector p629.
(3) p653 Kpnl/BamHI fragment; This fragment contains the firefly luciferase 
insert and SV40pA sequences from the original pGL2-basic vector plus the 4.7 kb 
Xhol/Kpnl fragment that is the 4.7 kb upstream region o f the human HO-1 promoter 
inserted next to the luciferase insert within the multiple cloning site of the vector.
It is worthy of note that the pGL2-Basic vector lacks eukaryotic promoter and 
enhancer sequences thus allowing maximum flexibility in the cloning o f putative 
regulatory sequences. Expression of luciferase activity in extracts of cells 
transfected with this plasmid depends on the insertion and proper orientation o f a 
functional promoter upstream of the genetic luciferase “/«c” element.
2.1.1. Propagation, Isolation and Purification of p706/HO4.7
The present project began by isolation and purification of p706/HO4.7 plasmid from 
an Escherichia coli (E. coli) strain “sure cut” bacterial strain (Promega, UK) that 
was originally transformed with this construct. For this purpose, the bacterial strain 
containing the p706/HO4.7 plasmid was cultured overnight on an Luria-Bertani 
(LB) agar plate (see section A. 1.9) supplemented with 100 pg/ml ampicillin (see 
section A. 1.1). After checking the controls, transfer single colony forming units 
from the LB agar plates into 10 ml o f LB broth containing the appropriate antibiotic.
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The cultures were grown overnight at 37°C on a shaking incubator at 300 rpm using 
the New Brunswick Scientific shaker (UK). The next day 5 ml portions o f each 
culture were inoculated into 150 ml o f LB broth containing the same antibiotic and 
this culture was grown overnight (i.e. 16-18 h) at 37°C on a shaking incubator. The 
next day, cell suspensions were centrifuged for 5 min at 14,000 rpm (10000 x g) in a 
microcentrifuge and the supernatant discarded. The pellets were resuspended in 
250 pi o f resuspension solution (see section A. 1.2) by gentle vortexing. This was 
followed by the addition o f 250 pi o f cell lysis solution (see section A. 1.3) to each 
suspension and the subsequent mixing by inversion in order to obtain a clear 
solution. The suspensions were neutralized with 350 pi of neutralization solution 
(see section A. 1.4) and then centrifuged at 14000 rpm (10000 x g) for 10 min. The 
supernatants were then removed and transferred to a barrel minicolumn/syringe 
assembly containing the DNA purification resin (Promega kit, UK). A vacuum was 
then applied to pull the lysate solution into the minicolumn. Thereafter to each 
column, 700 pi o f washing solution was added followed by the application o f a 
vacuum to draw the solution through the minicolumn. The latter procedure was 
repeated a second time. The minicolumns were then transferred into a 1.5 ml 
microcentrifuge tube (Tyco Healthcare Group, MA, USA) and centrifuged at 14000 
rpm (10000 x g) for 1 min to remove any possible residue. The minicolumns were 
then transferred into a clean 1.5 ml microcentrifuge tube. Finally, the isolated DNA 
was eluted from the column in TE buffer (see section A .l .5). This was incubated for 
10 min at 60°C and then spin at 14,000 rpm for 1 min.
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2.1.2. Methods for Quantification of p706/HO4.7 Plasmid DNA
2.1.2.1. Ethidium  Bromide Dot Analysis
Pure DNA solutions were prepared as standards at a series o f concentrations o f 0, 1, 
2.5, 5, 7.5, 10 and 20 pg/ml. To each 4 pi o f the standard and the DNA solutions 
under test (e.g. purified plasmids), 4 pi o f 1 pg/ml ethidium bromide (see section 
A. 1.6) was added.
The contents o f each tube were spotted into Saran plastic wrap (SOD, UK) covering 
a thin glass plate. The glass plate was then placed under a UV transilluminator and 
photographs were taken using a Polaroid MP4 camera and Polaroid 637 film. The 
fluorescence o f the unknown was compared with the fluorescence o f the different 
spots o f the standard DNA to estimate the approximate concentration o f the 





Figure 2.1. Estimation of the concentration of the DNA fragments by ethidium 
bromide dot analysis. Lane 1 contains the DNA standards dots at concentrations of 
0, 1, 2.5, 5, 7.5, 10 and 20 pg/ml and lane 2 contains the unknown DNA samples 
dots.
2.I.2.2. Spectrophotometer Quantification of p706/HO4.7 Plasmid DNA
Accurate estimation of the concentration of the DNA was then performed using the 
“GeneQuant II spectrophotometer” (Milton Roy Spectronic) as follows: 100 pi of 
H2O was placed in a reference cuvette to adjust zero level at 320 nm; 2 pi of this 
water was withdrawn and replaced with 2 pi of the DNA solution to be tested. The 
absorbance was read at 320 nm. The concentration of the DNA of the test solution 
was also obtained using the absorbance at 260 nm (A260) and 280 nm (A28o)- The 
purity of DNA in the original solution was determined as follows:
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Ratio = A260 / A 280-
Ratios between 1.8-2 were consistently obtained. The concentration of DNA was 
then calculated according to the following formula:
(j.g/ml DNA= Dilution factor x 50 x A260
2.1.3. Preparation of the pi06/BglII-KpnI DNA Fragment
Summary: To prepare a series of p706 constructs containing 1, 3 or 5 repeat o f
HNF-4 responsive elements, the Kpnl- BgUI insert o f p706/HO4.7 containing the 4.7
kb upstream promoter region o f the human HO-1 was removed in two steps as
follows:
The p706/HO4.7 plasmid was first digested with the Kpnl restriction enzyme. An 
aliquot of the reaction mixture was loaded on a 1% agarose gel (in 1 x TAE buffer) 
(see section A. 1.7) to monitor the level o f linearization o f the plasmid. Next, the 
reaction mixture containing the linearized p706/HO4.7 was purified by ethanol 
precipitation, and subjected to a second enzymatic digestion with the BgUI 
restriction enzyme. The digested material was then loaded on a 1% agarose gel (1 x 
TAE) and the p706/KpnI-BglII fragment was extracted from the gel and further 
purified by ethanol precipitation.
Subsections 2.1.3.1 to 2.1.3.5. describe in further detail the preparation of the p706/ 
KpnI-Bglll fragment
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2.1.3.1. Digestion of the Vector p706/HO4.7 w ith the Kpnl Restriction 
Endonuclease
The digestion reaction contained the components shown in Table 2.3.
Table 2.3.
Reagent Volume (pi)
DNA plasmid (p706/HO4.7 kb) 45 pi (= 20 pg)
Kpnl enzyme 80 units
(10 x) R E act®  4 buffer 10 pi
Milli-Q H20 37 pi
Total 100 pi
The above reaction was prepared in 5 replicates in microcentrifuge tubes and 
incubated overnight at 37°C. The next day, the samples were heated at 65°C for 10 
min to stop the enzymatic digestion, as this treatment inactivates the restriction 
enzymes.
Aliquots (3 pi) o f both digested and undigested DNA were then loaded on an 
agarose gel to test the successful effectiveness o f the restriction digestion; the 
loading mixture contained the components shown in Table 2.4.
Table 2.4.
Reagent Undigested vector Digested vector
Vector 3 pi 3 pi
6 x loading dye 3.3 pi 3.3 pi
Milli-Q H20 3.7 pi 3.7 pi
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The contents o f each tube were vortexed and loaded on a 1% agarose gel (1 x TAE).
2.1.3.2. P reparation  of an Agarose Gel in 1 x TAE Buffer
100 ml of 1% agarose gel was prepared as follows:
One gram o f electrophoresis grade agarose gel (Roche, Switzerland) was dissolved 
in 100 ml final volume o f 1 x TAE buffer to produce a 1% mixture, using a 
microwave oven for 2-3 min. The solution was cooled to about 60°C and poured 
into a casting tray. A comb was placed in the tray perpendicularly to allow the 
production o f wells for loading o f DNA samples. The width of each tooth o f the 
comb was 2 mm and the spaces between the teeth were 0.1 mm. The gel was 
allowed to set at room temperature for 30 min. The gel was given a further 10 min 
in the cold room (4°C) to solidify. The comb was removed carefully to reveal the 
wells.
2.1.3.3. Agarose Gel Electrophoresis
The gel tray was mounted in an electrophoresis tank (Bio-Rad mini-sub DNA cell) 
and submersed in 1 x TAE buffer.
3 pi o f marker, 10 pi o f undigested mixture and 10 pi o f digested mixture were then 
loaded into separate wells in the agarose gel. Electrophoresis was carried out at 120 
V for lh  to obtain full separation o f the bands. For the staining process the 
electrophoresis gel was removed and stained in a tank containing 1% ethidium 
bromide in 1 x TAE buffer for 10-15 minutes. The gel was visualized under UV 
light and photographed using a Polaroid MP4 camera and Polaroid 637 film. This 
gel is shown in Figure 2.2.
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Figure 2.2. Test of digestion of p706/HO4.7 with Kpnl-BglH on a 1% agarose 
gel (1 x TAE). Following digestion of p706/HO4.7 kb with the restriction enzymes 
Kpnl and Bglll alone or combined, the DNA was separated on a 1% agarose gel (1 x 
TAE). Lane 1 contains the 1 kb ladder. Lane 2 contains the undigested p706/HO4.7 
kb plasmid. Lane 3 contains the product of digestion of p706 with Kpnl restriction 
enzyme. Lane 4 contains the products of digestion of p706/HO4.7 plasmid with 
Bglll and Kpnl restriction enzymes and lane 5 contains the products of the digestion 
of p706/HO4.7kb with Bglll enzyme.
2.I.3.4. Ethanol Precipitation of the Products of the Enzymatic Digestion
To 97 pi of the reaction mixtures were added 10 pi of 3 M sodium acetate (pH 7.5) 
and 200 pi of absolute ethanol. The contents of the tubes were then left overnight at 
-20°C or for 15 min in an ethanol-dry ice bath. The DNA solutions were then 
centrifuged at 14000 rpm (10000 x g) for 30 min at 4°C. The supernatants were
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discarded and 50 pi of 70% ethanol was added to each tube to wash the DNA 
pellets. Following a further centrifugation at 14000 rpm (10000 x g) for 10 min 
(4°C), the supernatants were discarded and the pellets were air-dried for 5 min. The 
DNA pellets were resuspended in 45 pi TE buffer.
2.1.3.5. Digestion of the p706/HO4.7/Ap/i/ Fragment with the Bglll Restriction 
Endonuclease
The digestion reaction contained the components shown in Table 2.5.
Table 2.5.
Reagent Volume (pi)
DNA {pl06fWOA.ilKpnl) 45 pi (= 20 pg)
BgUI enzyme 80 units
10 x REact® 3 buffer 10 pi
Milli-Q H20 37 pi
Total 100 pi
The contents of each tube were mixed and incubated in a water bath at 37°C 
overnight.
2.I.3.6. Electrophoresis of the Digestion Mixture
A 1% agarose gel was prepared as described above and then placed into the 
electrophoresis tank containing 1800 ml o f 1 x TAE and 10 pi o f 1% ethidium
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bromide. The electrophoresis was carried out at 20 V overnight (16-18 h) at 4°C to 
separate the DNA bands. The gel was visualized under UV light and photographed 
using a Polaroid MP4 camera and Polaroid 637 film as shown in Figure 2.3.
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Figure 2.3. Test of digestion of p706/HO4.7 with KpnI-Bg/II on a 1% agarose 
gel (1 x TAE). Following digestion of p706/HO4.7 kb with the restriction enzymes 
Kpnl, and Bglll, the DNA was separated on a 1% agarose gel (1 x TAE). Lane 1 
contains the 1 kb ladder and lanes 2, 3, 4 and 5 contains the products of digestion of 
p706/HO4.7 plasmid with Bglll and Kpnl restriction enzymes performed in 4 
replicates.
2.I.3.7. Extraction and Purification of the p706IKpnl-BgUI Fragment from the 
Gel
The DNA bands (i.e. p706/KpnI-Bglll, 11.3 kb) were cut from the gel using a 
scalpel blade and extracted using the QIA X-extraction kit (QIAGEN, UK), in 
accordance with the manufacturer’s instructions.
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2.1.4. Preparation of the “insert” DNA
The purpose o f this section was to design and prepare a series o f 1, 3 and 5 repeat of 
HNF-4 responsive elements to be inserted within the Bglll-Kpnl sites o f the 
pl06/KpnI-BglII fragment vector. Subsections 2.1.4.1. to 2.1.4.4 describe in further 
detail the preparation of the HNF-4 responsive elements as “inserts”.
2.I.4.I. Design of the Oligonucleotides
The complementary oligonucleotides coding for the HNF-4 responsive element 
repeats were designed in such a way that when they annealed to each other they 
would produce the restriction sites Kpnl at the 5’-end and Bglll at the 3’-end. To 
further protect the restriction sites, 3 random additional bases were added at the two 
extremities of the designed oligonucleotides. These oligonucleotides were then 





5’ -ATCGGTACCGGGCAAAGTTCAAGATCTCAG- 3’ 
3’ -TAGCCATGGCCCGTTTCAAGTTCTAGAGTC- 5’
HNF4-3':
Kpnl HNF4 HNF4 HNF4














2.1.4.2. Annealing of the Oligonucleotides
To anneal the complementary strands, 1 pg o f each oligonucleotide was placed into 
a microcentrifuge tube and to this, 2 pi o f Tris-HCl buffer (pH 7.5), 20 pi of 100 
mM EDTA (pH 8.0) and 40 pi o f 0.5 M NaCl were added. The volume was then 
made up to 200 pi using autoclaved Milli-Q water. The reaction was incubated at 
96°C for 3 min and allowed to cool gradually to room temperature. The mixture 
was then stored at -20°C until subjected to polyacrylamide gel electrophoresis.
2.1.4.3. Purification and Isolation of the Annealed Oligonucleotides
To separate the annealed oligonucleotides from un-annealed or partially annealed 
material, the mixture was subjected to polyacrylamide gel electrophoresis
2.1.4.3.1. Preparation o f Polyacrylamide Gel Glass Plates
Two 18 cm glass plates were placed one on top o f the other separated by 1 mm thin 
plastic spacers on three sides. The edges o f the three sides were sealed using 3% 
molten agarose gel and the edges were fixed using three clips in each side.
2.1.43.2. Preparation o f the Non-denaturing Polyacrylamide Gel 
A 15% polyacrylamide (AccuGel, Flowgen, UK) gel was prepared as follows:
22.5 ml of 40% AccuGel (40%, 29:1, acrylamide: Bis-acrylamide) was placed in a 
beaker; to this 6 ml of 10 x TBE (see section A. 1.8) and 31.5 ml autoclaved Milli-Q 
H2O were added. The mixture was placed for 3 min in a water bath at 37°C and 
then cooled in an icebox for 10 seconds.
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2.1.4.3.3. Casting o f the Polyacrylamide Gel
To the 60 ml of the 15% acrylamide solution were added 250 pi of 10% ammonium 
persulfate (APS) and 48 pi TEMED. Mix the contents.
The solution was poured between the two glass plates. A comb with 8 mm wide 
teeth and 0.2 mm spaces between the teeth was placed perpendicular with teeth 
down between the two glass plates and allowed to polymerize for 1 h at room 
temperature and for 10 min at 4°C. The comb was then removed to reveal the wells.
2.1.4.3.4. Polyacrylamide Gel Electrophoresis
Eight hundred ml o f 1 x TBE buffer was poured into a vertical electrophoresis tank. 
The gel was immersed in the TBE buffer at the bottom of the tank and fixed with 
two clips in either side. The wells in the upper part o f the polyacrylamide gel were 
filled and covered with TBE buffer. Prior to loading the samples, the gel was pre­
run for 1 h at 250 V.
Twenty pi o f 6 x orange/blue loading dye (Promega, UK) were added to the 
annealed insert DNA and mixed. The order o f loading o f the samples to the gel was 
as follows: 100 pi o f the annealed mixture, 10 pi (0.5 mg/ml) of 10 bp DNA marker, 
3 pi (3700 ng) o f sense insert DNA mixed with 7 pi o f 6 x orange/blue loading dye, 
3 pi (3700 ng) o f anti-sense insert DNA mixed with 7 pi o f 6 x orange/blue loading 
dye.
The polyacrylamide gel was then run at 250 V for 4 h at room temperature to 
separate the bands. The gel was stained by immersing the gel for 20-30 min in a 0.5 
pg/ml ethidium bromide solution as described before. The gel was then removed 
and placed under UV light box to visualize the DNA bands. Photographs were 
taken using a Polaroid MP4 camera and a Polaroid 637 film as show in Figure 2.4.
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Figure 2.4. Polyacrylamide gel electrophoresis of annealed oligonucleotides.
Samples were loaded onto a 15% acrylamide gel and run for 4 h at 250 V. Lane 1 
contains a 10 bp ladder. Lanes 2 & 3 contains free complementary strands of 
HNF4-3' and lanes 4 & 5 contain the annealed oligonucleotides of HNF4-3' to form 
double strand fragments.
The annealed DNA bands were excised from the gel using a scalpel and transferred 
into 1.5 ml microcentrifuge tubes. These bands were then purified from the gel 
using a QIAGEN extraction Kit (QIAGEN, UK), in accordance with the 
manufacturer’s instructions. Finally, annealed DNA samples were resuspended in 
30 pi of TE buffer.
Two microlitres of the recovered double strand DNA inserts were then subjected to 
electrophoresis using a 3% agarose gel, to monitor the presence of annealed DNA 
fragments, and photographs were taken as shown in Figure 2.5.
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Figure 2.5. Analysis of the annealed DNA fragments in a 3%  Agarose gel. Lane 
1 contains a 100 bp DNA ladder. Lanes 2 & 3 contain the annealed DNA samples 
HNF4-5'.
2.I.4.4. Restriction of the Annealed DNA Fragments
To prepare the annealed DNA fragments for ligation into the p706/KpnI-Bglll 
vector, it was necessary to digest them with the restriction enzymes Kpnl and Bglll. 
This was achieved with two consecutive sets of digestions as follows:
2.1.4.4.1. Restriction o f  the DNA “inserts” with Kpn I  Restriction Endonuclease 
The first step was to digest the annealed DNA fragments with Kpn I  restriction 




“Insert” DNA 20 pi (=700 ng)
Kpnl enzyme 5 units
10 x REact® 4 buffer 3 pi
Milli-Q H20 6.5 pi
Total volume 30 pi
The solution was incubated at 37°C overnight as described before.
2.1.4.4.2. Ethanol Precipitation o f the “insert” DNA
To increase the yield o f precipitation of DNA by ethanol, the ethanol precipitation 
was performed in the presence of 2.5 pi o f 1 M MgCl2 and 1.5 pi of 2.5 pg/pl tRNA 
as a carrier. The pellets were resuspended in 30 pi o f TE buffer. Samples were then 
loaded in a 3% o f high resolution MetaPhor® agarose gel (FMC Bioproducts, UK) 
and run at 20 V in 0.5 X TBE (4°C) for 3 hours. Next, the gel was stained with 
ethidium bromide and photographed under UV light. An example of such analysis 
is shown in Figure 2.6.
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Figure 2.6. Test of digestion of the ‘insert” DNA fragments with K pnl and 
B g lll restriction enzymes. Samples were loaded on a 3% Metaphore agarose gel 
and run for 3 h at 20 V. Lane 1 contains the 10 bp DNA ladder. Lane 2 contains the 
undigested annealed insertion DNA (HNF4-5'). Lane 3 contains the insertion DNA 
digested with Kpnl which resulted in 2 fragments (i.e. the insert DNA digested with 
Kpnl and the tRNA band that was used as a carrier during ethanol precipitation). 
Lane 4 contains the product of digestion of the insertion DNA with Kpnl and Bglll 
enzymes, and lane 5 contains the 100 bp DNA ladder.
2.1.4.4.3. Restriction o f  the “insert” DNA Fragments with the Bgl 11 Restriction 
Endonuclease
Following the digestion of the ‘insert” DNA fragments with Kpnl, the inserts were 
subjected to a second set of digestion with Bglll to generate a Bglll restriction site.
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The digestion reaction contained the components shown in Table 2.7.
Table 2.7.
Reagent Volume (pi)
Insertion DNA 25 pi (= 700 ng)
Bglll enzyme 5 units
10 x REact®3 buffer 3 pi
Milli-Q H20 1.5 pi
Total volume 30 pi
The digestion was carried out at 37°C overnight as described before.
2.1.4.4.4. Extraction and Purification o f the “insert” DNA Fragments Following 
Digestion with Restriction Enzymes Kpnl and BgUI.
High-resolution 3% MetaPhor® agarose gels were produced by dissolving the 
MetaPhor® in 0.5 x TAE buffer at a low temperature in a microwave oven for 10 
min. Electrophoresis was carried out at 20 V in the cold room at 4°C for 3 h to give 
full separation of the bands.
At the end of the run, gels were stained with ethidium bromide in 0.5 x TAE for 10 
minutes. The DNA bands were visualized using a UV light box. Photographs were 




Figure 2.7. Analysis of the “ insert” DNA fragments prior to extraction and 
purification. Following digestions, the samples were loaded on a 3% Metaphor 
agarose gel for 3 h at 20 V. Lane 1 contains the 10 bp DNA ladder. Lane 2 contains 
the undigested annealed “insert’ DNA (HNF4-3'). Lane 3 contains the “insert” 
DNA (HNF4-3') digested with Kpn I  and Bgl II. Lane 4 contains the undigested 
annealed “insert” DNA (HNF4-5'). Lane 5 contains the “insert” DNA (HNF4-5') 
digested with Kpn I  and Bgl II  and lane 6 contains the 100 bp DNA ladder.
Bands from lane 3 and 5 were excited from the agarose gel and purified using the 
QIAGEN extraction Kit (QIAGEN, UK) protocol. The yield of the eluted material 
was then estimated by two methods, i.e. either by measuring the absorbance of DNA 
at 260 nm and 280 nm using the GeneQuant II spectrophotometer as described 
before or with ethidium bromide dot analysis.
A l l  bp 




The concentration of the “insert” and the vector DNA to be used in the ligation were 
calculated. For every ligation two ratios o f vector: insert DNA were tried, i.e.l :1 
and 1:3. The latter ratio was found to be optimum. The following equation was 
used to calculate the quantity (i.e. ng) o f the “insert” DNA required:
ng o f vector x kb size o f insert insert
ng o f insert = ---------------------------------------------  x molar ratio o f --------
kb size o f vector vector
The ligation reaction mixture is shown in Table 2.8.
Table 2.8.
Reagent Volume (pi)
Vector DNA 105 ng
Insert DNA 105 (ratio l:l) or 300ng (ratio 1:3)
Ligase 10 x buffer 3 pi
T4 DNA ligase (Boehringer, lunit/pl) 1 pi
Milli-Q H2O to 30 pi
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A number o f controls were included in every ligation:
• Vector, no insert DNA, no ligase enzyme, but plus ligase buffer and Milli-Q 
water.
•  Vector, no insert DNA but plus ligase enzyme, ligase buffer and Milli-Q 
water.
• Vector, insert DNA (ratio 1:3), no ligase enzyme, but plus ligase buffer and 
Milli-Q water.
' •  Vector, insert DNA (ratio 1:1), no ligase enzyme but plus ligase buffer and 
Milli-Q water.
Where insert DNA or ligase enzyme was not included in the reaction mix the 
volume was made up to 10 pi with the addition o f a greater proportion o f Milli-Q 
water.
The reaction mixes were incubated overnight (16 h) at 12°C. Next morning 5 pi o f 
each ligation mixture containing the ligated DNA (i.e. p706/HNF4-l', p706/HNF4- 
3' or p706/HNF4-5') was transformed into JM109 competent cells using the 
protocol outlined in section 2.1.6.
For transformation reactions, in addition to the ligation control, two additional 
controls were used. The first was a negative control and involved the transformation 
procedure without the addition o f DNA (replaced by water) and the second, a 
positive control, were uncut vector was transformed.
2.1.6. Preparation of Competent 2?. coli JM109 Cells
Escherichia coli (E. coli) strain JM109 (Promega, UK), the host strain was used for 
all o f the plasmids. Competent E. coli cells were prepared as follows:
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A single colony o f E. coli JM109 was picked from a fresh agar plate and innoculated 
into 5 ml o f LB medium and incubated at 37°C overnight in a shaking incubator. 
The following morning, 1 ml o f culture was diluted to 100 ml with LB and grown 
under standard conditions until the optical density (OD at 550 nm) of the solution 
reached 0.48 (2.5-3 h). The cell suspension was then chilled on ice for 5 min and 
centrifuged in sterile falcon tubes for 5 min, 6000 rpm (Beckman J2-MC) at 4°C.
The supernatant was discarded and the cells re-suspended in 40 ml o f Tfb I buffer
i,L
(see section A .l .11) (2/5 volume of culture) and chilled on ice for 5 minutes. Cells 
were then centrifuged at 6000 rpm (Beckman J2-MC) for 5 min at 4°C and the 
supernatant discarded. Cells were subsequently re-suspended in 4 ml (2/25th volume 
o f culture) o f Tfb II buffer (see section A. 1.12) and chilled on ice for 15 minutes. 
Cells were stored in 200 pi aliquots, snap frozen in a dry-ice/methanol bath and 
stored at -70°C  until required.
2.1.7. Transformation of Competent E. coli JM109 Cells with the Vectors 
p706/HNF4-l\ p706/HNF4-3' and p706/HNF4-5\
Two hundred microlitres o f competent cell suspension were thawed at room 
temperature and then placed on ice for 10 minutes. Plasmid DNA (<100 ng) was 
then added and gently mixed using a Gilson tip followed by incubation on ice for 
30-45 minutes. The cells were heat shocked by incubation at 43°C for 45 sec and 
then returned to ice for 2 minutes. The cell suspension was then diluted to 800 pi 
with LB broth followed by incubation at 37°C for one and a half hours. After this, 
100 pi of the cell culture was plated out onto a LB agar plate containing ampicillin 
at a concentration o f 100 pg/ml. Plates were incubated overnight at 37°C.
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2.1.8. Colony Picking and Small-Scale Plasmid Purification
After checking the transformation controls, a sterile wire loop was used to transfer 
single colony forming units from the LB plates into 10 ml o f LB broth containing 
the appropriate antibiotic. The cultures were grown overnight at 37°C on a shaking 
incubator at 300 rpm. The next day 10 ml of the LB broth containing the vector of 
interest was inoculated into 250 ml o f LB broth containing the same antibiotic and 
the cultures were grown overnight at 37°C on a shaking incubator.
Plasmid DNA was purified using a modified version o f the alkaline lysis method 
described by Sambrook et al (1989).
2.1.9. Polymerase Chain Reaction
To check that the purified plasmids contained the HNF4-repeats as ‘inserts’, the 
DNA constructs were subjected to polymerase chain reaction (PCR) to amplify the 
region containing the HNF-4 inserts. For this purpose, two sets o f oligonucleotides 
i.e., ‘sense’ (Right primer 5’ see section 2.1.4.1) and ‘anti-sense’ primers (Left 
primer 3’ see section 2.1.4.1) encompassing the region surrounding the insert were 
designed. Then, a master mix combining multiples o f the reaction components 
listed below was assembled as outlined in Table 2.9. This master mix reduced 
variation when working with multiple DNA samples. The master mix was in a final 





Volume per 50pl reaction Final concentration
10 X PCR buffer 5 pi 1 X
M gCb 50 mM 2 pi 2 mM
dNTPs 10 mM 1 pi 200 pM
Right primer 10 pM 1 pi 0.5 pM
Left primer 10 pM 1 pi 0.5 pM
Platinum Taq
DNA polymerase (5 U/pl)
0.5 pi 0.05 U/pl
Plasmid DNA 1 pi 0.2 pg
Milli-Q H20 50 pi
The polymerase reaction consisted of the following stages, 94°C for 5 min (1 cycle); 
followed by three 1 min steps at 94°C, 50°C and 72°C (25 cycles); and finally 72°C 
for 7 min (1 cycle) using a Crocodile II temperature cycle (Perkin Elmer, UK). This 
protocol was based on the Taq DNA polymerase method (Chou et ah, 1992). The 
PCR sample was then run on a 3% agarose gel and photographed under UV light as 
shown in F igure 2.8.
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Figure 2.8. PCR analysis of the p706/HNF-4 constructs. Following the PCR 
reaction, an aliquot of the PCR products were run on a 3% agarose gel for 1 h at 90 
V. Lane 1 contains the 1 kb ladder. Lanes 2 to 5 contain the PCR products of 
p706/HNF4-5' plasmids and lane 6 contains the 25 bp ladder.
2.1.10. Sequencing
To further verify that the p706/HNF-4 constructs contain the expected HNF-4 
sequence and repeats, DNA sequencing was carried out at the automated DNA 
sequencing facility in the Department of Biology and Biochemistry at the University 
of Bath using the Wisconsin Genetics Computer Group (GCG) software package on 
the University of Bath GENOME Unix server. The DNA samples for sequencing 
were supplied in 200 pi PCR tubes and contained 200-500 ng of DNA (plasmid), 10
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pmol o f the specific primers designed for the vector. The total volume of the 
samples was made up to a volume o f 6 pi with Milli-Q water.
2.1.11. Insertion of the SV40 Promoter into p706-Derived Plasmids
Since the p706/HNF-4 plasmids lacked eukaryotic functional promoter elements for 
successful expression o f the luciferase gene, it was necessary to incorporate a 
Simian virus 40 (SV40) promoter that contained the RNA polymerase II elements 
for initiation o f transcription, upstream o f the “/wc+” and downstream of the HNF-4- 
enhancer elements. For this purpose, the p706/HNF4-l', 3' or 5' constructs were 
digested with BgUI and Hindlll restriction enzymes as described before. 
Meanwhile, the SV40 promoter from pGL3 promoter (Promega, UK) vector was 
restricted and gel purified as shown in Figure 2.9. This was followed by ligation of 
the SV40/Bglll-Hindlll promoter fragment into the pl06/BglII-HindIII fragment. 
The resulting plasmid constructs were called as p706/SV40 i.e. p706 lacking the 4.7 
kb HO promoter but containing the SV40 promoter, p706/HNF4-17SV40, 
p706/HNF4-37SV40 and p706/HNF4-57SV40 i.e. p706/HNF4 plasmids all 





Figure 2.9. Test of digestion of pGL3 with KpnI-Hindlll on a 1% agarose gel.
Following digestion, the DNA samples were separated on a 1% agarose gel (1 x 
TAE) for 16 h at 20 V. Lane 1 contains the 1 kb DNA ladder. Lane 2 & 3 contain 




All biochemicals were of analytical grade and purchased from Sigma Chemicals, 
UK, except where indicated.
All the solutions used for the preparation o f culture medium for mammalian cells 
were obtained from Gibco BRL, (Life Technologies, UK) except where indicated.
B .l. Cell Culture Solutions 
B.1.1. Water
Fresh Milli-Q water was used for the preparation o f all culture media and solutions 
and was obtained from a Milli-Q PF Plus system with ultrafiltration cartridge 
(Millipore UK Ltd.).
B.1.2. Phosphate Buffered Saline
Phosphate buffered saline solution (PBS) tablets without magnesium or calcium ions 
were obtained from (Oxoid Ltd, UK). One tablet was dissolved in 100ml of Milli-Q 
water with a final pH of 7.3. Solutions were sterilised by autoclaving at 121°C for 
15 minutes.
B.1.3. Trypsin-EDTA
0.05% (w/v) o f Trypsin and 0.02% (w/v) EDTA.
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B.1.4. Culture Media Additives
The culture media for human cells used in this study was the Dulbecco’s Modified 
Eagle’s Medium (DMEM) that was purchased as 1 x concentration. They were 
supplied with glutamax-1, sodium pyrovate, 1000 M G/L glucose, pyrodoxin and 
contained phenol red as an indicator.
B.1.5. Animal Sera
Fdetal Bovine Serum (FBS), heat inactivated.
B.1.6. Antibiotics and Antimycotics 
B. 1.6.1. Penicillin/ Streptomycin
These antibiotics were dispensed as 5 ml vials at concentrations o f 10 units/ml 
penicillin (penicillin G, sodium salt) and 10 pg/ml streptomycin (streptomycin 
sulphate) per milliliter o f normal saline.
B.l.6.2. Fungizone
The fungizone is an antimycotic reagent comprised o f a solution of 0.5 pg/ml 
amphotericine B, prepared in Milli-Q water.
B. 1.6.3. Hygromycin B
This product was purchased at a concentration o f 50 mg/ml in PBS.
Hygromycin B is an aminoglycosidic antibiotic produced by streptomyces 
hygroscopicus that kills bacteria and fungi.
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B.1.7. Miscellaneous Products for Cell Culture 
B.l.7.1. MEM Non-essential Amino Acids (MEM-NEAA)
Non-essential amino acids were obtained as 100 x concentration, and they were 
supplied without L-glutamine.
B.l.7.2. Opti-MEM®
Opti-MEM®, is a serum-free growth medium specifically designed for transfection 
experiments.
B.l.7.3. Trypan Blue
Trypan blue, used for assessing cell viability, was obtained from BDH Laboratory 
Reagents Ltd. and was prepared as a 0.4% (w/v) solution in PBS.
B.l.7.4. LIPOFECTIN® Reagent
LIPOFECTIN® reagent was obtained as a 1:1 (w/w) liposome formulation o f the 
cationic lipid N-[l-[2,3-dioleyloxy] propyl]]—N,N,N-trimethyl-ammonium chloride 
(DOTMA) in membrane-filtered water which is suitable for the transfection o f DNA 
into tissue culture cells.
Growth media were prepared aseptically by adding to the 500 ml o f DMEM (10% 
[v/v] FBS) 60 ml o f FBS, 5 ml of Penicillin/ Streptomycin, 5 ml of MEM-NEAA, 
and 1 ml of Fungizone.
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B.2. Cell Culture Equipment
All aseptic techniques were carried out in a laminar flow cabinet (MDH Ltd) 
designed for vertical re-circulation o f air. Cells were cultured in a LEEC PF2 
humidified atmosphere at 37°C with 5% CO2 (v/v) 95% air incubator (Laboratory 
and Engineering Company). Cells were visually assessed daily for evidence o f 
microbial contamination under an inverted light microscope (WILD M4 Wild 
Heerbrugg Ltd).
B.3. Cell Culture Disposable Items
Sterile 75 cm and 175 cm top tissue culture flasks were obtained from Fermentas, 
UK. Six and ninety-six well plates were obtained from Nunc, (Denmark). 
Cryopreservation ampoules used for storing frozen cells in liquid nitrogen were 
obtained from Coming, UK.
2.2. Cell Culture Methods
2.2.1. Cell Lines
HepG2 cell line: A human hepatocellular carcinoma cell line.
In the present study, this cell line was used as a model for liver cells. HepG2 cells 
were obtained form ATCC (USA), and were grown in DMEM medium containing 
10% FBS, Penicillin/ Streptomycin and MEM non-essential amino acids. For 
routine culture, cells were seeded at a density o f 3 x 105 cells in 10 cm plastic plates 
and were grown either for 4 days to reach 80% confluency or for 5 days to reach
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90% confluency. The medium was changed every 48 hours. The cells were 
passaged by trypsinisation once a week and were used for experiments.
HtTA cells: a human cervix carcinoma, Hela derivative and transformed cell line. 
The HtTA cell line was derived from Hela cells being stably transfected with a 
tetracycline-controlled transactivator (tTA) consisting o f the tet repressor fused with 
the activating domain of virion protein 16 of the herpes simplex virus (HSV).
HtTA was kindly obtained from the laboratory Professor Rex M. Tyrrell (Pharmacy 
and Pharmacology Department) and were grown in DMEM medium containing 10% 
FBS, Penicillin/ Streptomycin and MEM non-essential amino acids. Cells were
■i
seeded at a density of 2 x 10 in 10 cm plastic plates and were grown for 2 days to 
reach 90% confluency. The cells were trypsinised for passage every 3 days and 
were used for experiments.
2.2.2. Subculturing of Cell Lines Using the Trypsinisation Technique
For subculture, 175 cm flasks containing the monolayers o f each cell line were 
rinsed three times with 10 ml aliquots of PBS and then incubated at 37°C with 2 ml 
of 0.25% Trypsin solution for approximately 5 min. Detached cells were diluted to 
20 ml with complete culture medium and were then centrifuged at 1000 rpm (700 x 
g) for 10 min at room temperature. The supernatants were discarded and the cell 
pellets were resuspended in 1ml o f culture medium for a viable count using a 
hemocytometer. Next, an appropriate aliquot o f each cell suspension was 
transferred to a sterile 175 cm flask containing 50 ml o f fresh culture medium.
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2.2.3. Estim ation o f the Cell Num bers
To determine the number o f cells, a viable count was performed using a 
hemocytometer. Following detachment o f cells from the flask, the cell suspension 
was briefly vortexed to break up the clumps of cells. 12 pi of well-suspended cells 
were mixed with an equal volume of trypan blue solution. The sample was loaded 
into an etched glass chamber with raised sides that will hold a quartz coverslip
0.1mm above the chamber floor. Viable cells were detected by a bright ‘halo’ light 
around their cell membrane whereas dead cells were permeabilised by the dye and 
stained blue. The viable cell numbers in the four squares surrounding the central 
square were counted and this was repeated for the other side of the hemocytometer 
chamber, using an inverted light microscope. The viable cell concentration in the 
original suspension was calculated using the following equation:
Total cell count in 4 squares x 5 x 105
Cell concentration per milliliter = ----------------------------------------------------
Number o f squares (4)
2.2.4. Cell Storage and Recovery
Cells were prepared for storage by detachment of a confluent monolayer by 
trypsinisation as described above followed by centrifugation at 1000 rpm (700 x g) 
for 10 min. The supernatant was then discarded and the cell pellets were 
resuspended in the growth media at a concentration o f 2 x 105 cells/ml. A cell 
freezing solution was prepared in a filter-sterilised solution o f 25 ml FBS 
supplemented with 10% (v/v) dimethylsulphoxide (DMSO) (spectrophotometric
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grade) as a cryopreservative in a glass bottle. Next, 0.4 ml o f cell suspension was 
dispensed in 1.8 ml aliquots with 0.6 ml o f the freezing solution into Coming tubes, 
transferred to isopropylalcohol in -70°C overnight, then fitted into a Union Carbide 
LR-40 liquid nitrogen freezer where they were stored at approximately -148°C.
For cell recovery, the contents of an ampoule were thawed rapidly by brief 
incubation in a 37°C water bath followed by dilution with 10 ml o f fresh medium. 
Cells were centrifuged for 10 minutes at 1000 rpm (700 x g) and the supernatant was 
discarded. The cells were then resuspended in 10 ml o f fresh medium and then 
transferred into a 175cm flask containing 50 ml o f medium and then incubated 
under standard culture conditions. Cells were cultured for at least two passages in 
order to establish them before any experiments were carried out.
2.2.5. Transfection of DNA into the Cells
2.2.5.1. Cell culture in 6-well Plates
Following the determination of the concentration o f the cell lines, the cells were 
transferred into 6-well plates. Cells were seeded at a density such that at the time of 
transfection monolayers were 40-50% confluent.
2.2.5.2. Preparation of Transfection Complexes
2.2.5.2.1. Preparation o f Solution A
For each transfection, a mixture o f 2 pg o f DNA plasmid o f interest (i.e. P706 
derivatives) and/or 0.25 pg of a reference plasmid (i.e. the p-galactosidase 
expression vector ‘pCMVpGal’ obtained from CLONTECH, UK) were diluted to 
100 pi with serum free medium Opti-MEM in a sterile 1.5 ml microcentrifuge tube, 
gently mixed and incubated for 30 min at room temperature. This cotransfection
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was performed simultaneously to enable differences in transfection and growth to be 
corrected.
2.2.5.2.2. Preparation o f Solution B
For each transfection, variable quantities of lipofectin reagent (i.e. 5-20 pi) were 
diluted to 100 pi with Opti-MEM, gently mixed and incubated for 30 min at room 
temperature.
Complexes were prepared by adding 100 pi o f solution B to 100 pi o f solution A. 
The complex solution was gently mixed by pipetting the solution up and down (i.e. 4 
times). The mixture was then incubated at room temperature for 20 min. 
Meanwhile, monolayers o f cells were washed once with warm Opti-MEM and 
800pl o f this medium were added to each well. 200 pi o f the complex solution were 
added to each well.
The transfection was then carried out for 4-5 hours at 37°C after which, the 
transfection medium was replaced with the fresh complete culture medium and cells 
were incubated for a further hour before harvesting for analysis.
For all transfection studies, each data point represents the mean ± standard deviation 
(± SD) o f triplicate samples and each experiment was repeated on at least three to 
four occasions.
2.2.5.3. Addition of Hygromycin B
To maintain the expression o f hygromycin B resistant p706 and p706-derivative 
plasmids, following transfection hygromycin B was added to each well plate at a 
concentration of 150 pg per ml o f media.
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2.2.6. Preparaion of Cell Lysates for Further Assays
2.2.6.1. Detergent Lysis Method
After the appropriate period o f post-transfection incubation, the cell monolayers 
were first washed twice with 2 ml of PBS and then treated with 115 pi o f lysis 
buffer (see section A. 1.10) per well followed by freezing at -70°C. The next day, 
the samples were thawed at room temperature for 30 min and the cell extracts were 
scraped from the culture dish, collected and transferred into sterile 1.5 ml 
microcentrifuge tubes and centrifuged for 10 min at 1000 rpm (700 x g) and the 
supernatant was used for analysis.
2.2.7. Luciferase Reporter Assay
Luciferase levels within cells were quantified using the Promega luciferase assay 
system (Promega, UK) according to the manufacturers instructions (Technical 
Bulletin, Promega, UK). As little as 10' moles o f firefly luciferase can be 
measured using this kit. A light unit versus relative enzyme concentration was 
constructed using purified firefly luciferase.
A series o f solutions was prepared by dilution o f purified luciferase (Promega, UK) 
stock with 10 ml assay buffer (Promega, UK). After centrifugation o f the cell lysate 
(from section 2.2.6), 20 pi o f room temperature cell extract (supernatant) were 
mixed with 100 pi o f luciferase assay reagent (luciferase assay substrate +10 ml of 
assay buffer) again at room temperature, using luciferase reagent as a reference. 
The disposable test tube (Promega, UK) containing the reaction was quickly 
vortexed and then immediately placed into the luminometer (TD-20/20) to measure 
the light intensity produced. The instrument settings were as follows: sensitivity
25.1, delay 5 seconds, integration 10 seconds and repeats 3 times.
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2.2.8. Protein Assay
The protein content in cell extracts was measured using the Bradford Assay 
(BioRad, Germany). Samples and standards were prepared according to the 
manufacture’s protocol and calibration curves for protein were constructed using 
bovine serum albumin (BSA) as a standard. Briefly, the BSA stock solution (100 
mg/ml, Roche) was first diluted in water to the final concentration o f 1 mg/ml and 
then standards were prepared in tubes as indicated in Table 2.10.
Table 2.10.The standard curve using BSA as protein 










The samples were prepared by mixing 20 pi o f cell extract (supernatant) with 780 pi 
o f H2O. Next, 200 pi of Bradford reagent was added to each tube and the mixture 
was immediately vortexed to reveal the formation o f the blue colored Biorad/protein 
complexes. 100 pi of each tube was then added to a 96 well microplate and the
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concentration o f the proteins in the cell lysates was determined at 595 nm using the 
Dynatech MR5000 microplate-reader by the Biolinx-Rad, 2.1 software program. 
The protein concentrations were calculated by linear regression from the standard 
curve.
2.2.9. p-galactosidase Assay
P-galactosidase activity was determined 48 h following the cotransfection as 
follows: 50 pi of cell extract was incubated with 150 pi o f reagent containing 2.5 
mM Chlorophenol Red P-galactopyranoside (CPRG) (Boehringer Mannheim, 
Mannheim, Germany) and 1.25 mM MgC^. The activity o f p-galactosidase was 
calculated from the absorbance at 550 nm obtained in the final reaction using a 96- 
well microplate reader (Dynatech MR5000).
2.2.10. Green Fluorescence Assay
Green fluorescent protein (GFP) is a bioluminescent protein that originates from 
Renilla reniformis. The bioluminescence is expressed as bright green waves o f light 
that run across the surface of the cells. The source of this green light is the 
fluorescence from a protein containing an unusual chromophoric group.
To determine the efficiency o f transfection in the cell lines used in this study, the 
plasmid pEGFP/CMV was used. In this plasmid, the ‘enhanced green fluorescent 
protein (EGFP)’ has been cloned downstream of the CMV (cytomegalovirus) 
promoter in pEGFP (4.7 kb), the enhanced green fluorescent protein vector was 
obtained from CLONTECH, UK. This vector was transfected into both the HepG2 
and HtTA and cell lines fluorescence activated cell sorter (FACS) analysis was used
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to quantify both the level of transfection and expression o f the GFP in both cell 
lines.
Briefly, monolayers of HepG2 and HtTA cell lines grown on 10 cm plates were 
transfected with EGFP vector using the lipofectin and then incubated with the 
appropriate compounds for 48 hours. The media was then removed and saved. The 
cells were washed twice with PBS and incubated for 5 min with 3ml o f 0.25% w/v 
trypsin. After detachment, 3 ml o f saved media was reapplied to the cells and the 
cells were transferred to a flow cytometer tube (Becton Dickinson, UK). The cells 
were spin into a pellet by centrifugation at 1000 rpm (700 x g) for 5 min in a Jouan 
CR412 centrifuge. The supernatant was removed and replaced with 5 ml o f PBS. 
The resultant suspension was then analysed on a (FACS) Vantage SE (Becton 
Dickinson, UK) using emission wavelength fluorescence at 535 nm under specific 
excitation at 435 nm.
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CHAPTER 3 RESULT 1
One-way o f targeting gene expression in vivo is to control transcription using a 
tissue specific regulatory system. Tissue specific promoters or enhancers are used in 
transgenic animals and could be utilised in medicines for gene therapy.
In the introduction section (1.1.5.1.) we have discussed the transcription factors 
(TFs) that are enriched in the liver. At present the usual methods for selection o f a 
tissue specific promoter is to identify a gene which is expressed at high level in the 
target tissue and then to use the promoter for this gene to drive the expression of 
another therapeutic gene in the target tissue. Alternatively one could examine the 
TF-binding sites within a population o f known promoters to identify TFs that are 
associated with a target tissue/organ specific expression.
In the present study we have used both approaches to identify the TF-responsive 
elements associated with the liver specific expression.
In this section we describe how the following computer analyses allowed us to 
identify specific promoter TF-binding sites that are abundant in the liver.
1. First a literature search was carried out on human liver promoters using the 
Gene B ank D atabase. This led us to the identification o f up to 50 
promoters isolated from the human liver promoter sequences. This analysis 
also contained information about their access number, sequence and a short 
explanation about the origin of the species.
2. Data obtained from Gene B ank was then catalogued using V ECTO R NTI 
program and the data were analysed in order to identify the promoters in the 
DNA sequences and the TF- binding sites for each promoter. VECTOR 
NTI is a software package that can integrate sequence analysis software
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solution for molecular biologists, since it visualizes, constructs and stores 
analysis o f biological molecules. It is therefore a convenient housekeeping 
system for storage o f data.
3. Further analysis of the promoters was carried out using the TFSEARCH 
algorithms at the following web site
[http://www.rwcp.or.jp/lab/adappl/papia.html]. The TFSEARCH is a 
Japanese program that allows the identification o f the potential binding 
elements o f TFs as shown in Figure 3.1. Furthermore, TFSEARCH 
identifies consensus sequences for each transcription factor using consensus 
data, which is available in the TFMATREX database as shown in Figure
3.2.
TFSEARCH Search Result
** TFSEARCH ver.1.3 ** (c)1995 Yutaka Akiyama {Kyoto Univ.)
This simple routine searches highly correlated sequence fragments 
versus TFMATRIX transcription factor binding site profile database 
by E.Wingender, R.Knueppel, P.Dietze, H.Karas (GBF-Braunschweig).
<Warning> Scoring scheme is so straightforward in this version.
score * 100.0 * {'weighted sum' - min) / (max - min)
The score does not properly reflect statistical significance!
Database: TRANSFAC MATRIX TABLE, Rel.3.3 06-01-1998 
Query: PGL3 (650 bases)
Taxonomy: ALL
Threshold: 85.0 point
TFMATRIX entries with High-scoring:
1 CCCGGGAGGT ACCGAGCTCT TACGCGTGCT AGCTCGAGAT CTAAGTAAGC entry
---------- > M00263 StuAp 89.2
 <----------  MO0263 StuAp 87.7
 <  M00123 c-Myc/ 86.8
 ----> MO0048 ADR1 86.2
51 TTGGCATTCC GGTACTGTTG GTAAAATGGA AGACGCCAAA AACATAAAGA entry score
—  M00028 HSF 100.0
 <  MOOiOQ CdxA 96.2
—  M00Q29 HSF 96.0
------- > MOOL48 SRY 90.9
  m 60148 SRY 90.0
<-------  M00050 E2F 87.4
 <  M0Q101 CdxA 87.1
<---- M00029 HSF 86.3
<------- M002 53 cap 85.3
Figure 3.1: An example o f the data obtained for TF-binding sites in TFSEARCH 
program.
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DT 18.10.94 (created); ew±.




DB heat shock factor (Drosophila)
XX
BE T00386; HSTF; Species: fruit fly, Drosophila melanogaster. 
XX
P0 A C G T
01 31 14 4 1 A
02 0 0 50 0 G
03 48 2 0 0 A
04 43 1 5 1 A
05 23 1 14 12 N
XX
BA 50 functional genomic HSEs
CC not included are sequences with more them 2 mismatches at positions 
CC 2 to 4; the matrix only describes the properties of the basic 
CC 5-bp unit of which three have to be present to constitute a minimal H3E 
XX
RN II]
RA Fernandes M., Xiao H., Lis J. T.
RT Fine structure analyses of the Drosophila and saccharomy.ces 
RT heat shock factor-heat shock element interactions 
RL Nucleic Acids Res. 22:167-173 (1994).
XX
/ /
Figure 3.2: An example o f the data obtained from TFMATREX program.
4. In this example, consensus sequences containing more than 6 nucleotides 
were considered to be “long sequences” whereas those having less than 6 
nucleotides were considered to be “short sequences”. The assumption was 
that “long sequences” would be more specific elements. Table 3.1 
summarizes data obtained from the TFSEARCH on number o f TF-binding 
sites having long sequence and Table 3.2 summarizes the TF-binding sites 
having short sequences. The data obtained from the TFSEARCH also 
provide information about the number o f TF-binding sites and their 
prevalence within the promoters studied. Both tables show the percentage of 
the promoters, which have at least one potential site for each TF.
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Table 3.1: TF-binding sites having long sequences more than 6bp.
Name Total num ber %  Percentage
IRF-1 3 18.75%
NF-kB 2 12.5%













Table 3.2: TF-binding sites having short sequences less than 6 bp.















5. A literature search was carried out using BIDS, to deduce which promoters 
are active in the liver but not in other organs. Sixteen o f the promoters were 
thought to be liver specific; 34 others were known to promote expression of 
their corresponding genes in other organs. An attempt was made to examine 
the liver specificity o f each response element by calculating the percentage 
of the promoters, which had each response element. A comparison was
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made between the TF-binding elements present in liver promoters having 
long sequences with those present having short sequences as shown in 
Tables 3.1 and 3.2. If a TF-binding element was present in a high 
percentage of liver promoter with long sequences, but not in short group, it 
was assumed that these elements were worthy o f further investigation.
6. Another separate approach to identify liver-specific promoters was to use 
BIDS to identify promoters for the 16 genes which are more commonly 
expressed in the liver i.e. promoters for albumin, cytochrome P450 
isoenzymes, plus enzymes from hepatic mitochondria inner membrane 
compartment. The latter enzymes play an important role in the metabolism 
of cholesterol and the related sterols. The metabolic steps are carried out by 
hepatic mitochondria cytochrome P450 (Mullick, 1995). A survey of data in 
the gene bank revealed 19 promoters o f cytochrome p450 isoenzymes. A 
comparison of these promoters was made as before using TFSEARCH and 
the data was compared with the previous 16 liver specific promoters.
7. A book called TRANSCRIPTION FACTORS ESSENTIAL DATA (Locker, 
1996) is an attempt to present the essential data for each TF such as how it 
functions in regulating transcription, relationship to other proteins and where 
it is expressed, and includes some tables about tissue specific regulators. 
The suggested liver specific TF-binding sites are ANF, AT-rich, C/EBP, 
HLF, and HNF-4 as shown in Table 3.3.
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Table 3.3: Potential liver specific TFs, where K= G or T, Y= C or T, W= A or T, 









BZIP/PAR C/EBP site Enhancer
binding
protein
HNF-4 KGC WARGKY C 
AY
ZnF HNF4 site Hepatocyte 
nuclear factor
ATBF1-A ATTAATAATTAC Hom/ZnF AT-rich site Zinc-finger
homeodomain
protein
HLF GTTACGTAAT BZIP/PAR HLF site Hepatic
leukaemia
factor




And other liver specific transcription factors that are not yet defined are shown in 
Table 3.4.
Table 3.4. Liver specific TF’s that are not well defined
Element Binding Site Family
Conexin 32 gene AAGCTCCGGTCCT
GGGCTGCTTGT
Not cloned




The analysis carried out in this study suggested that the most likely liver specific 
TFs are those listed in Table 3.5.
Table 3.5. Suggested liver specific transcription factors.
Factor Binding site Family Element Name
HNF-4 KGC WARGKY C 
AY




BZIP/PAR C/EBP site Enhancer
binding
protein
H LF GTTACGTAAT BZIP/PAR HLF site Hepatic
leukaemia
factor




In general there are hundreds o f known TFs but it is assumed that in total there may 
be thousands of other TFs yet to be isolated. Hepatocyte-specific gene expression is 
determined by TFs o f several families, which were initially identified by their 
binding sites in the regulatory regions of genes that are expressed specifically in the 
liver. These factors belong to four different families, including homeodomain 
homolog “HNF-1” (Frain et al., 1989), the basic leucine zipper protein “C/EBP”, the
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forkhead homolog “HNF3” (Lai, 1991), and an orphan steroid hormone receptor 
“HNF4” (Sladek et a l , 1990). All of these TFs were found to be expressed not only 
in the liver but also in the kidney, intestine, pancreas and spleen (Zaret, 1994). Cell- 
specific transcription o f these factors is an important element o f their distribution in 
specific cell types and the determination o f expression is established requires 
knowledge o f the regulation o f the genes for these factors during embryogenesis 
(Xanthopoulos et al, 1991).
109
CHAPTER 4 Result 2
The unique phenotype of hepatocytes arises from the expression of genes in a liver- 
specific fashion, which is controlled primarily at the level of mRNA synthesis. By 
analyzing DNA sequences implicated in liver-specific transcription, it has been possible 
to identify members of the nuclear proteins such as the liver-enriched /raws-activating 
factors, HNF-1, HNF-3, HNF-4, HNF6, C/EBP and DBP, which are key elements in the 
liver specific transcriptional regulation of genes. Each of these factors binds to unique 
DNA sequences (cw-acting elements) in the promoter and enhancer regions of genes 
expressed in terminally differentiated hepatocytes such as albumin. The determination 
of the tissue distribution of these factors and analysis of their hierarchical relations has 
led to the hypothesis that the cooperation of liver-enriched transcription factors with the 
ubiquitous rraws-activating factors is necessary, and possibly even sufficient for the 
maintenance of liver specific gene transcription (see section 1.1.5.1. and Result 1 
Table 3.5.).
In the present study, the HNF-4 binding site was chosen as the most proven liver 
specific regulatory element (see Result 1) to test the hypothesis that a tandem repeat of 
these liver-enriched transcription factor binding sites linked upstream of a luciferase 
gene within a reporter plasmid would increase the basal level expression of the 
luciferase gene in a liver-specific cell line when compared to a non-liver cells.
To this regard we made several constructs using the EBV-based p706 plasmid that 
contained a series of 1’, 3’ and 5’ repeats o f HNF-4 binding sites upstream of the
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luciferase gene (i.e. after removing the 4.7 kb fragment containing the upstream 
promoter region of HO-1 gene, see 2.1.3). The resulting plasmids were called as 
p706/HNF4-l’, p706/HNF4-3’ and p706/HNF4-5\ respectively. The restriction 
analysis confirmed that the 4.7 kb upstream promoter region of HO-1 was removed, 
reducing the size of p706 DNA plasmid from 16 kb to 11.3 kb (see 2.1.3). The 
sequencing confirmed that the ligation of HNF-4 into p706 was successful (see M ap 2 
and Figure 4.1.). Furthermore since the p706/HNF-4 plasmids lacked eukaryotic 
functional promoter elements for successful expression of the luciferase gene, it was 
necessary to incorporate a promoter (i.e. SV40 promoter from PGL3 promoter plasmid) 
upstream of the “/wc+” and downstream of the HNF4 regulatory element(s). The 
resulting plasmid constructs were called as p706/SV40 (i.e. p706 lacking the 4.7 kb HO 
promoter but containing the SV40 promoter) as shown in M ap 3, p706/HNF4-17SV40, 
p706/HNF4-37SV40 and p706/HNF4-57SV40 (i.e. P706/HNF4 plasmids all containing 
the SV40 promoter). The sequencing confirmed that the insertion of the SV40 into 
p706/HNF-4 plasmids was successful (see M ap 4 and Figure 4.2.).
We then transiently transfected these vectors into two human carcinoma cell lines, 
HepG2 (liver-specific cells) and HtTAl (Hela derived non-liver cells) and then 
monitored the level of luciferase expression within the lysates of transfected cells. 
Since EBV-based episomal vectors have the advantage of autonomous replication and 
their expression can be maintained for several days under hygromycin, the basal level 
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Figure 4.1. Confirmation of the insertion of HNF-4 repeats between Kpnl and Bglll 
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Figure 4.2. Confirmation of the insertion of HNF-4 1’ and SV40 between Kpnl and 









To reinforce the time course data obtained with the luciferase activity and as an internal 
control, in each set of experiments both cell lines were also co-transfected in parallel 
with CMV-pgal and 48 h later both the luciferase and P-galactosidase activities were 
measured in each sample. The reason for choosing the 48 h time point for P- 
galactosidase activity was that during a series of initial experiments, it was found that 
the maximum peak of this enzymatic activity within the transient transfected cells was 
around 48 h after which the p-galactosidase activity dropped rapidly to the background 
level (i.e. within the following 24 h, data not shown). Therefore for normalization and 
as an internal control for possible differences in the transfection efficiency, the 
luciferase activity (i.e. RLU/mg protein) o f the 48 h time point was divided by P-gal 
activity (i.e. P-gal/mg protein) and expressed as RLU/p-gal.
4.1. The Transient Expression o f p706/HNF4/SV40 Plasmids
The first approach was to determine the transient basal level expression of luciferase 
gene following transfection of HepG2 cells with the p706/HNF-4/SV40 plasmids. The 
methodology involved the transfection of the cells with p706/HNF4/SV40 plasmids, 
followed by lysis of the cells 10, 24, 48, 72, 96 and 120 h following transfection assays. 
The level of luciferase activity was then measured in the cells and expressed as 
RLU/mg protein.
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Figure 4.1.1.A summarizes the time course studies of the luciferase activity in HepG2 
cells transfected with either p706/SV40 or p706/HNF4-l VSV40, p706/HNF4-37SV40 
and p706/HNF4-57SV40 plasmids. The results showed that the presence HNF-4 
elements appear to repress the basal level of luciferase activity in HepG2 cells. Indeed 
the level of luciferase activity in cells transfected with p706/HNF4-17SV40 was two to 
three fold lower than that of p706/SV40 alone. The luciferase activity dropped even 
more when HepG2 cells were transfected with p706/HNF4-37SV40. The transfection 
of HepG2 cells with p706/HNF4-57SV40 revealed no basal luciferase activity when 
compared to p706/SV40-transfected cells.
Figure 4.1.2.A summarizes the time course studies of the luciferase activity in HtTA-1 
cells transfected with either p706/SV40 or p706/HNF4-17SV40, p706/HNF4-37SV40 
and p706/HNF4-57SV40 plasmids. The results showed that the presence HNF-4 
elements also repress the basal level of luciferase activity in these cells, although to 
much lesser extent than in HepG2-transfected cells. The normalization of luciferase 
activity to p-galactosidase at 48 h time point showed similar data to those normalized 
per mg protein, indicating that both normalization methods can be used for the 
interpretation of the data obtained (Figure 4.I.I.B. and 4.1.2.B).
Overall, it appeared that the presence of HNF-4 elements upstream of SV40 represses 
significantly the basal level of luciferase activity in both cell lines. However the 
comparison of the level of luciferase activity in cells transfected with p706/SV40 
revealed that this level was significantly higher in HepG2 cells when compared to
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HtTA-1, suggesting that SV40 promoter o f pGL3 should contain m-acting elements 
that are liver-specific. Indeed the computer analysis using the TFSEARCH program 
(see Appendix 4.1.1) revealed that this promoter contains an element that resembles the 
liver-enriched transcription factor-binding site for C/EBP. The C/EBP is a transcription 
factor that is highly enriched in the liver and is known to regulate the expression of 
liver-specific genes such as albumin and the cytochrome-P450 (CYP2D5) (Kel et al., 
2001). Thus the C/EBP may, at least in part, regulate the expression of the luciferase 
gene in HepG2 cells.
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Figure 4.1.1. Functional analysis of liver-enriched HNF-4 regulaory elements in 
transiently transfected HepG2 cells. A. The time course o f basal level o f  luciferase activity 
follow ing transient transfection o f HepG2 cells with the p706/SV 40 and p 706/H N F 4-17SV 40, 
P 706/H N F 4-37SV 40 and P706/H N F 4-57SV 40 reporter plasmids. The transfected cells were 
kept in the tissue culture media with hygrom vcin. The luciferase activity was measured 10, 24, 
48, 72 , 96 and 120 h follow ing transfection assays and expressed as RLU/m g protein. B. The 
normalised basal luciferase activity measured 48 h follow ing co-transfection o f  HepG2 cells 
with the p706/SV 40 and p706/H N F4/SV 40 constructs and CM Vp-gal reporter plasm ids. The 
transfected cells were kept in the media with hygrom vcin. The luciferase activity was 
normalised to p-galactosidase activity and expressed as RLU/p-gal. Data are means +  S.D . o f  4  
independent experiments. The Student M est was used to evaluate the statistical significance 
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Figure 4.1.2. Functional analysis of liver-enriched HNF-4 regulaory elements in 
transiently transfected HtTA-1 cells. A. The time course o f  basal level o f  luciferase activity  
fo llow ing transient transfection o f HtTA-1 cells with the p706/SV 40 and p 706/H N F 4-17SV 40, 
p706/H N F 4-3’/S V 40  and p706/H N F 4-5’/SV 40 reporter plasmids. The transfected cells were 
kept in the tissue culture media with hygrom vcin. The luciferase activity was measured 10, 24, 
48, 72 , 96 and 120 h follow ing transfection assays and expressed as RLU/m g protein. B. The 
normalised basal luciferase activity measured 48 h follow ing co-transfection o f  HtTA-1 cells 
with the p706/SV 40 and p706/H N F4/SV 40 constructs and CM Vp-gal reporter plasmids. The 
transfected ce lls were kept in the media with hygrom vcin. The luciferase activity was 
normalised to p-galactosidase activity and expressed as RLU/p-gal. Data are means + S.D. o f  4
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independent experiments. The Student r-test was used to evaluate the statistical significance 
(p<0.05) o f  each data point.
A ppendix 4.1.1: Sequence o f 230 bp o f the SV 40 prom oter o f the PG L-3 p lasm id.





CGC CCCTAACTCCGCCCATCCCG CCCCTAACTC CGCCCAGTTC CGCCCATTCT 
AP-1
CCGCCCCATC GCTG ACT A ATTTTTTTT ATT TATGCAGAGG CCGAGGCCGC CTCGGCCTCT 





CHAPTER 5 Result 3
The expression of HO-1 is known to be particularly high in the liver (Maines, 1988), 
presumably because this gene contains a series o f liver-specific regulatory elements 
within its 5’-flanking promoter region that contribute to its higher basal level 
expression. The purpose o f this section was to identify such potential upstream 
promoter regions containing key ds-acting elements that regulate the tissue-preferential 
basal expression o f the HO-1 gene. To this regard, the p706-EBV-based luciferase 
reporter plasmids that contained progressive deletions within the 4.7 kb upstream 
promoter region o f the human HO-1 gene were transiently transfected into two human 
carcinoma cell lines, HepG2 (liver-specific cells) and HtTAl (Hela derived non-liver 
cells) and then the level o f luciferase expression was monitored within the lysates of 
transfected cells. Since EBV-based episomal vectors have the advantage of 
autonomous replication and their expression can be maintained for several days under 
hygromycin, the basal level expression of luciferase in these constructs was followed 
up to 5 days following transient transfection. A database program TFSEARCH was 
then used to locate the transcription factor elements within the 4.7 kb o f the 5’-flanking 
region of human HO-1.
5.7. The Transient Expression o f  p706/HO4.7 Plasmid
The first approach was to determine the transient basal level expression o f luciferase 
gene under the control o f the 4.7 kb o f 5’-flanking region of the human HO-1 gene 
following transfection o f both HepG2 and HtTAl cells with the p706 /H 04.7 plasmid 
(16 kb). The methodology involved the transfection o f the cells with p706/HO4.7,
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followed by lysis o f the cells 10, 24, 48, 72, 96 and 120 h following transfection assays. 
Furthermore a comparison was made between the transient basal level expression of 
luciferase o f cells maintained either with or without hygromycin. The level of 
luciferase activity was then measured in the cells under both conditions and expressed 
as RLU/mg protein.
Figure 5.1.1. summarizes the time course studies o f the luciferase activity in both 
HepG2 and HtTA-1 cells. As shown the basal level o f luciferase activity in HtTA-1 
cells did not significantly change till 120 h following transient transfection. However 
in comparison, the level of this enzymatic activity was significantly increased in 
HepG2 cells especially from 48 h up to 120 h post-transfection time points. This 
sustained increase in luciferase activity in the transfected HepG2 cells was observed 
under both Hygromycin-selected (Figure 5.1.1.C) and unselected conditions (Figure
5.1.1.A). However the addition of hygromycin as the selection marker significantly 
decreased the level o f RLU/mg protein in both transfected HepG2 and HtTA-1 cells, 
indicating that omitting the selection marker could affect the evaluation o f the data 
obtained.
The fact that the basal level o f luciferase activity was significantly higher in liver- 
specific HepG2 cells when compared to the non-liver HtTA-1 cells was consistent with 
the hypothesis that the 4.7 kb upstream promoter region of HO-1 should contain many 
key liver-specific cis-acting regulatory elements. However to ascertain that such 
difference in basal level expression o f luciferase was not due to variability in 
transfection efficiencies between the two cell lines, we performed the following control 
experiments:
>  To reinforce the time course data obtained with the luciferase activity and as an 
internal control, in each set o f experiments both cell lines were also co-
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transfected in parallel with CMV-Pgal and 48 h later both the luciferase and P- 
galactosidase activities were measured in each sample. The reason for choosing 
the 48 h time point for P-galactosidase activity was that during a series o f initial 
experiments, it was found that the maximum peak o f this enzymatic activity 
within the transient transfected cells was around 48 h after which the P- 
galactosidase activity dropped rapidly to the background level (i.e. within the 
following 24 h, data not shown). Therefore for normalization and as an internal 
control for possible differences in the transfection efficiency, the luciferase 
activity (i.e. RLU/mg protein) o f the 48 h time point was divided by P-gal 
activity (i.e. p-gal/mg protein) and expressed as RLU/p-gal.
The normalization o f luciferase activity to p-galactosidase at 48 h time point showed 
similar data to those normalized per mg protein, indicating that both normalization 
methods can be used for the interpretation o f the data obtained (Figure 5.I.I.B.,
5.1.l.D. and 5.1.2.A)
>  Moreover for each experiment a series o f additional controls were used such as 
mock-transfected cells (i.e. cells that were undergone the transfection procedure 
using DNA-free transfection mixtures), CMVp-gal-transfected cells alone, plus 
the transfection of cells with an independent reporter plasmid called pEGFP that 
expresses the green fluorescent protein under control o f CMV promoter. For 
most o f these controls, the data were analysed 48 h following the transfection 
assays, (see Figure 5.1.2.).
Figure 5.1.2. shows representative examples o f these control experiments performed 
48 h following the transient transfection assays. The comparison o f the level o f P-gal 
activity in these two cell lines indicated that the transfection efficiency of these two cell
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lines are in the same range of 18 to 21 as a result the level o f normalised luciferase 
activity is always higher in HepG2 cells than HtTA-1 cells (Figure 5.1.2.A). Similarly, 
when these two cell lines were transfected with an independent reporter plasmid (i.e. 
pEGFP) the estimated percentage o f transfection efficiency in flow cytometry (i.e. the 
observed shift in fluorescence with respect to X-axis) was in the very close range of 
60% to 70%. The fluorograms o f a representative expression are included in Figure
5.1.2. B to 5.I.2.E.
This i set o f data is consistent with the notion that the differences in basal level 
expression o f luciferase in cells transfected with p706/HO4.7 are not due to variability 
in transfection efficiencies between the two cell lines, but rather related to the 
tissue/cell-preferential expression o f this enzyme that functions under the control of 
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Figure 5.1.1. Functional analysis o f 4.7 kb o f human HO-1 5’-flanking upstream promoter 
region in transient transfection assays. A. The tim e course o f  basal level o f  luciferase activity  
fo llow in g  transient transfection o f  H epG 2 (black square) and HtTA-1 (red circle) ce lls  w ith the 
p 706 /H O 4.7  reporter plasm id. The transfected ce lls  were kept in the tissue culture m edia  
without hygrom vcin. The luciferase activity w as m easured 10, 24, 48 , 72 , 96  and 120 h 
fo llow in g  transient transfection assays and expressed  as R L U /m g protein. B. The norm alised  
basal luciferase activity m easured 48  h fo llow in g  co-transfection o f  H epG 2 and HtTA-1 cells  
with the p 706/H O 4.7  and C M V p-gal reporter plasm ids. The transfected ce lls  were kept in the 
m edia without hygrom vcin . The luciferase activity w as norm alised to P-galactosidase activity  
and expressed as R LU /p-gal. C . The tim e course o f  basal level o f  luciferase activity fo llow in g  
transient transfection o f  H epG 2 (black square) and HtTA-1 (red circle) ce lls  w ith the 
p 706 /H O 4.7  reporter plasm id. The transfection procedure and tim e points were sim ilar to (A ) 
excep t that the transfected ce lls were incubated in the m edia containing hygrom vcin . D. The 
norm alised basal luciferase activity m easured 48  h fo llow in g  transient co-transfection o f  
H epG 2 and HtTA-1 cells with the p 706 /H O 4.7  and C M V p-gal reporter plasm ids. The 
transfection procedure and normalization o f  the data w as sim ilar to (B ) excep t that the 
transfected cells were incubated in the m edia containing hygrom vcin . Data are m eans + S .D . o f  
3 to 4 independent experim ents. The Student /-test w as used to evaluate the statistical 
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Figure 5.1.2. Comparison of the transfection efficiency between HepG2 and HtTa-1 cell 
lines. A. The basal level o f  luciferase activity 48 h fo llow in g  transient transfection o f  HepG2 
and HtTA-1 ce lls  w ith either the p706/H O 4.7 reporter plasm id alone or com bined w ith CM V- 
(3-gal reporter plasm id. The data are m eans +  S .D . o f  3 to 4  independent experim ents. B. The 
fluorogram  show ing the background fluorescence o f  m ock-transfected HepG2 ce lls . The X- 
axis sh ow s the fluorescence intensity and the Y -axis is the ce ll counts C . The fluorogram  o f  
the expression o f  GFP 48  h after transient transfection o f  H epG 2 ce lls  w ith pEGFP plasm id. D. 
The background fluorescence o f  m ock-transfected HtTA-1 ce lls . E . The fluorogram  o f  the 
expression  o f  GFP 48  h fo llow in g  transient transfection o f  HtTA-1 ce lls  with pEGFP plasm id.
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5.2. The Transient Expression of p  706/HO Sequence Deletion-Mutant
Plasmids
The p706/HO4.7 and its sequence-deletion mutant plasmids were originally constructed 
by Larry Richman in the laboratory o f Prof. Tyrrell (Pharmacy and Pharmacology 
Department) to identify the UVA-responsive elements present within the 5’-flanking 
region o f the HO-1 gene. Since the Dnase I hypersensitive (HS) sites within the 
mammalian chromatin are often located within the 5’-flanking region of the active 
genes and are usually associated with functional sequences such as an ‘enhancer’, 
‘silencer’ or ‘promoter’, Tyrrell and co-workers determined the HS sites within the 4.7 
kb o f 5’-flanking region of the human HO-1 gene using the method developed by Wu 
et a l , (1979). These investigations (unpublished data) resulted in the identification o f 
three HS sites called HS-1 (approximate position from -70  to +30), HS-2 (approximate 
position -280 to -180) and HS-3 (approximate position -3650 to -4080). The HS-3 site 
overlapped with a region homologous to the mouse enhancer elements (E l). The 
p706/HO sequence deletion mutants were prepared by partial or complete deletion of 
the HS sites and their surrounding regions.
Figure 5.2.1. shows a diagrammatic representation o f the HS sites mapped within the
4.7 kb of 5’-flanking region o f the human HO-1 and the sequence-deletion analysis 
performed on p706-derived vectors.
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A brief description o f these sequence-deletion mutant plasmids is outlined below:
• p706 (i.e. p706/HO4.7) contains the full 4.7 kb o f the 5 '-flanking region o f the 
human HO-1 until plus 30 bp downstream of the transcription initiation site i.e. 
from nucleotide position -4740 to +19 so this construct contains the HS-1, HS-2 
and HS-3 sites.
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• p725 has a minimal deletion in cadmium responses element (Cd RE) from 
nucleotide position -3900 to -3740. This region overlaps with functional parts 
o f HS-3 and minimal mouse enhancer region SX2.
• p714 contains the complete HS sites but has deletions in two regions: (1) 
Deletion from nucleotide position -3560 to -380; (2) Deletion from nucleotide 
position —4740 to -4200.
• p717 contains only the HS-3 site and has deletions in two major regions: (1) 
Deletion from nucleotide position -3560 to +1, which contains the proximal 
promoter region as well as the complete HS-2 and the partial HS-1 sites; (2) 
Deletion from nucleotide position —4740 to —4200.
•  p718 contains the intact mouse enhancer region but has deletions in two major 
regions: (1) Deletion from nucleotide position -3740 to +1, which contains the 
proximal promoter region, the complete HS-2 and partial HS-1 sites plus a
130
partial deletion o f HS-3 site until the mouse enhancer region; (2) Deletion from 
nucleotide position -4740 to -4200.
• p722 has a major deletion o f the full 4.7 kb 5’-flanking promoter region from 
positions —4740 to +1 and contains only the partial sequence o f the HS-1 i.e. 
position +1 to +19.
• p736 contains the intact HS-2 site and has deletions in two regions: (1) Partial 
deletion o f HS-1 site from nucleotide position +19 to +30; (2) Deletion from 
position -4740 to -3740 that contains most o f the HS-3 site plus the entire
t
mouse enhancer region containing the Cd RE and its upstream region.
• p737 contains the intact HS-2 site and has deletions in two regions: (1) Partial 
deletion o f HS-1 site from nucleotide position +19 to +30; (2) Deletion from 
nucleotide position —4740 to -912 that contains deletions o f HS-3 site plus the
4-9entire mouse enhancer site containing the Cd RE and its upstream region.
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Figure 5.2.1. A diagrammatic representation of the HS and partial restriction- 
endonucleases sites mapped within the 4.7 kb of 5’-flanking region of the human HO-1 
and its sequence-deletion analysis on p706-derived vectors.
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To identify the potential upstream promoter regions o f HO-1 containing the czs-acting 
elements that contribute to tissue-preferential expression o f HO-1 gene, both HepG2 
and HtTA-1 cell lines were transfected with p706/HO sequence deletion mutant 
reporter plasmids. The latter reporter plasmids contained a series o f sequence deletions 
within the 4.7 kb o f the 5’-flanking promoter region o f human HO-1 gene. The 
luciferase activity was measured 10, 24, 48, 72, 96 and 120 h following transfection 
assays and expressed as RLU/mg protein. To reinforce the time course data obtained 
with the luciferase activity and as an internal control, in each set o f experiments both 
cell lines were also co-transfected in parallel with CMV-Pgal and 48 h later the 
luciferase activity was normalised to p-galactosidase activity and expressed as RLU/p- 
gal.
Figure 5.2.2 to Figure 5.2.5. summarise the data obtained from these transfection 
assays in both HepG2 and HtTA-1 cell lines, respectively. Some o f the main 
observations are outlined below:
(1) The first observation was that the basal level o f luciferase activity o f the mutant 
reporter plasmids in HepG2-transfected cells was overall higher than in HtTA-
1 -transfected cells.
(2) Secondly, as shown in Figure 5.2.2.A., in HepG2 cells, the 260 bp Cd+2RE 
deletion from nucleotide position -3900 to -3740 in p725 reporter plasmid 
resulted in a significant reduction (i.e. 3 to 6 fold reduction) of the promoter 
activity when compared to that of p706/HO4.7 plasmid. This reduction was 
also observed in HtTA-1 cells (Figure 5.2.3.A.) although to a lesser extent (i.e.
2 to 4 fold reduction).
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(3) As shown in Figure 5.2.2.A., the basal level of luciferase activity in HepG2 
cells transfected with p717 and p718 was similar and significantly higher than 
those cells transfected with p725 although the former mutant constructs 
contained major deletions within the 4.7 kb upstream promoter region i.e. A 
common deletion from nucleotide positions -4740 to -4200 and then different 
deletions in p717 from nucleotide position -3560 to +1 and in p718 from
. nucleotide position -3740 to +1. These data suggest that firstly the region -  
3740 to -3560 does not contain any significant element responsible for basal
i1
promoter activity and that secondly the HS-3/ mouse enhancer/ Cd RE region 
must contain positive liver-preferential regulatory elements as the basal activity 
o f luciferase in HtTA-1 cells transfected with p717 and p718 is very low and 
similar to that of p725 (Figure 5.2.3.A.).
(4) Interestingly, the basal level o f luciferase activity in HepG2 cells transfected 
with p714 plasmid was extremely low and comparable to that o f p722 that 
contains the complete deletion of the 4.7 kb upstream promoter region o f the 
human HO-1 gene. The comparison of p714 mutant construct with p717 and 
p718 strongly suggest that the region -380 to +1 should contain liver- 
preferential negative regulatory elements, as the transient expression of 
luciferase in HtTA-1 cells transfected with p714 was relatively high and almost 
similar to that o f p706 (Figure 5.2.2.A. and Figure 5.2.3.A.).
(5) The basal level of luciferase activity in HepG2 cells transfected with p737 was 
relatively high and similar to the activity observed with p717 and p718. The
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comparison o f the expression o f luciferase activity in HepG2 and HtTA-1 cells 
transfected with this reporter plasmid suggests that the proximal promoter o f the 
HO-1 from nucleotide position -912 to +1 should contain liver-preferential 
positive regulatory elements (Figure 5.2.2.A. and Figure 5.2.4.A.).
(6) Finally the basal level of luciferase activity in HepG2 cells transfected with 
p736 was the highest activity observed among the p706 sequence deletion 
mutants, strongly indicating that the region -3740 to -912 should contain most 
of the positive regulatory elements for liver-preferential expression of HO-1 
gene. Indeed the transfection of this reporter plasmid in HtTA-1 cells did not 
modify the low basal level o f luciferase activity in these cells (Figure 5.2.4.A. 
and Figure 5.2.5.A.).
In all these transfection assays the data normalised by P-gal (i.e. 48 h post-transfection 
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Figure 5.2.2. Functional analysis of human HO-1 5 ’-flanking sequence-deletion mutants 
p714, p717, p718, p722 and p725 in transiently transfected HepG2 cells. A. The time 
course of basal level of luciferase activity following transient transfection of HepG2 cells with 
the p706/HO4.7 and p706/HO-sequence deletion mutant reporter plasmids. The transfected 
cells were kept in the tissue culture media with hygromvcin. The luciferase activity was 
measured following transfection assays expressed as RLU/mg protein. B. The normalised basal 
luciferase activity measured 48 h following co-transfection of HepG2 cells with the p706/HO 
mutants and CMV(5-gal reporter plasmids. The transfected cells were kept in the media with 
hygromvcin. The luciferase activity was normalised to P-galactosidase activity and expressed 
as RLU/p-gal. Data are means + S.D. of 3 independent experiments. The Student Mest was 
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Figure 5.2.3. Functional analysis of human HO-1 5 ’-flanking sequence-deletion mutants 
P714, P717, P718, P722 and P725 in transiently transfected HtTA-1 cells. A. The time 
course of the basal level of luciferase activity following transient transfection of HtTA-1 cells 
with the p706/HO4.7 and P706/HO-sequence deletion mutant reporter plasmids. The 
transfected cells were kept in the tissue culture media with hygromvcin. The luciferase activity 
was measured following transfection assays and expressed as RLU/mg protein. B. The 
normalised basal luciferase activity measured 48 h following co-transfection of HtTA-1 cells 
with the P706/HO mutants and CMV(3-gal reporter plasmids. The transfected cells were kept in 
the media with hygromvcin. The luciferase activity was normalised to (3-galactosidase activity 
and expressed as RLU/p-gal. Data are means + S.D. of 4 to 5 independent experiments. The 
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Figure 5.2.4. Functional analysis of human HO-1 5 ’-flanking sequence-deletion mutants 
p736 and p737 in transiently transfected HepG2 cells. A. The time course of basal level of 
luciferase activity following transient transfection of HepG2 cells with the p706/HO4.7 and 
p706/HO-sequence deletion mutant reporter plasmids in the presence of hygromvcin. The 
luciferase activity was measured following transfection assays and expressed as RLU/mg 
protein. B. The normalised basal luciferase activity measured 48 h following co-transfection of 
HepG2 cells with the p706/HO mutants and CMVp-gal reporter plasmids. The transfected cells 
were kept in the media with hygromvcin. The luciferase activity was normalised to p- 
galactosidase activity and expressed as RLU/p-gal. Data are means + S.D. of 4 to 5 
independent experiments. The Student /-test was used to evaluate the statistical significance 
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Figure 5.2.5. Functional analysis of human HO-1 5 ’-flanking sequence-deletion mutants 
p736 and p737 in transient transfected HtTA-1 cells. A. The time course of basal level of 
luciferase activity following transient transfection of HtTA-1 cells with the p706/HO4.7 and 
p706/HO-sequence deletion mutant reporter plasmids in presence of hygromvcin. The 
luciferase activity was measured following transfection assays and expressed as RLU/mg 
protein. B. The normalised basal luciferase activity measured 48 h following co-transfection of 
HtTA-1 cells with the p706/HO mutants and CMVp-gal reporter plasmids. The transfected 
cells were kept in the media with hygromvcin. The luciferase activity was normalised to (3- 
galactosidase activity and expressed as RLU/(3-gal. Data are means + S.D. of 3 to 4 
independent experiments. The Student Mest was used to evaluate the statistical significance 
(p<0.01) of each data point.
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5.5. Computer Analysis o f  the Regulatory Regions o f  the 5 ’-Flanking 
Region o f  the Human HO-1 Gene
To identify the potential cis-acting elements that might play a role in the modulation o f 
the basal level o f luciferase activity in transfection assays involving the sequence- 
deletion mutant reporter plasmids, a TFSEARCH computer program was used to locate 
the regulatory elements within the 4.7 kb o f the 5’-flanking region o f the human HO-1 
gene. Furthermore because o f the extensive research data available from studies 
carried out in the mouse HO-1 gene, the TFSEARCH was also performed within the
4.7 kb o f the 5’-flanking in the mouse HO-1 gene to compare the potential regulatory 
elements between the 4.7 kb o f 5’-flanking region o f human and murine HO-1 gene. 
The Appendix 5.3.1 and Appendix 5.3.2 summarises the main findings of the 
TFSEARCH analysis for both human and mouse HO-1 gene, respectively. The cis- 
regulatory elements that have been previously identified and published are shown in 
bold characters. The computer research o f the present study has also revealed 
numerous new binding sites for several known transcription factors, although within 
the appendix, only the most relevant ones are indicated.
The comparison o f the TFSEARCH data and the sequence-deletion mutant transfection 
assays suggest some ds-acting elements as potential candidate for liver-preferential 
expression o f human HO-1 gene. A summary o f this comparative study is outlined 
below:
>  As mentioned previously the Cd RE region (from nucleotide position -3740 to 
-3900) appears to contain liver-preferential positive regulatory elements. This
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fragment indeed contains the C/EBP(3 site. The C/EBPp is a transcription factor 
that is highly enriched in the liver and is known to regulate the expression of 
liver-specific genes such as albumin and the cytochrome-P450 (CYP2D5) (Kel 
et al., 2001). Thus the C/EBPp may, at least in part, regulate the expression of 
the HO-1 gene in HepG2 cells.
>  Also the fact that the basal level of luciferase activity in HepG2 cells transfected 
with p717 and p718 was similar and significantly higher than those cells 
transfected with p725 further suggested that the region -4200 to -3740 should 
contain positive liver-preferential regulatory elements. The computer analysis
I ^
revealed that in addition to the C/EBPp site present within the Cd RE, the 
region -4200 to -3740 contains a second C/EBPp site situated between 
nucleotide positions -4058 and —4045. Moreover this region is rich in critical 
regulatory elements such as AP-1 (2 sites), AP-4, NF-E2 and StRE sites. These 
transcription binding sites were also present within the SV40 promoter site of 
pGL-3 that when inserted into p706-based EBV vector, it dramatically 
increased the level o f luciferase activity in HepG2 cells only (see Result 2, 
Figure 4.1.1.). From these data a picture emerges suggesting that these 
regulatory elements might have a role in liver-preferential gene expression.
>  The comparison of the luciferase activity in HepG2 cells transfected with p714 
and those transfected with p717 and p718 mutant constructs strongly suggested 
that the region -380 to +1 should contain liver-preferential negative regulatory 
elements. The TFSEARCH and the published data from the literature (see 
introduction section 1.2.6.1.) reveal the presence of several critical binding 
sites such as AP-2 (two sites), AP-4, USF and NF-kB. Furthermore this region 
contains the highly polymorphic (GT)n repeats that are thought to act as a
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repressor o f the human HO-1 transcriptional activation (Kimpara et al, 1997). 
Because o f the polymorphic nature o f these dinucleotide repeats and its 
importance in negative regulation o f gene transcription (Yamada et a l, 2000), 
the number of these repeats is now carefully monitored within the promoter 
region o f the genes. For this reason, we have also monitored these repeats 
within the 5’-flanking region o f the p706/HO4.7 by sequencing its first 1 kb 
fragment. This analysis (Appendix 5.3.3) revealed that indeed these GT 
repeats (i.e. 29.repeats) are located within the proximal promoter region 
between nucleotide positions -197 and -258.
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Appendix 5.3.1: Sequence of 4.7 kbp of the 5’-region of the Human HO-1 gene.
The DNA sequences that resemble the transcription factor elements are highlighted in 
yellow. To distinguish between two attached consecutive binding elements, the 
highlight of one of the elements has been changed to light blue colour. The published 
transcription factor binding sites in highlighted yellow boxes are indicated in bold'. 
The HS sites are underlined in blue. The GT repeats within the HS-2 are indicated in 
‘bold’. The mouse enhancer site within the HS-3 are indicated in dark blue. The 
Cd+2RE sequences within the HS-3 highlighted in
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Appendix 5.3.2: Sequence of 4.7 kb of the 5’-region of the mouse HO-1 gene. The
DNA sequences that resemble the transcription factor elements are highlighted in 
yellow. To distinguish between two attached consecutive binding elements, the 
highlight of one of the elements has been changed to light blue colour. The published 
transcription factor binding sites in highlighted yellow boxes are indicated in ‘bold’. 
The CT repeats are underlined. The published enhancer elements SX2 in bold dark 
blue.


















































Continued (Appendix 5.3.2: Sequence of 4.7 kb of the 5'-























































Continued (Appendix 5.3.2: Sequence of 4.7 kb of the 5’-region of the mouse HO-1
gene).
















Appendix 5.3.3: Sequence of 1.4 kb from the 4.7 kb 5’-flanking HO-1 insert in 
P706/HO4.7 plasmid. The DNA sequences that resemble the transcription factor 
elements are highlighted in yellow. The GT repeats are underlined in bold. The 
restriction sites are typed in red. The transcription initiation site is shown in asterisk.













- 5 7 6
TCTCTGTTTTTTGACAGGAACTCAAAAAACAGATCCTAAATGTACATTTAAAGAGGGTGTGAGGAGGCAA 
GCAGTCAGCAGAGGATTCCAGCAGGTGACATTTTAGGGAGCTGGAGACAGCAGAGCCTGGGGTTGCTAAG 
B g l  1 HSE
TTCCTGATGTTGCCCACCAGGCTATTGCTCTGAGCAGCGCTGCCTCCCAGCTTTCTGGAACCTTCTGGGA 
CGCCTGGGGTGCATCAAGTCCCAAGGGGACAGGGAGCAGAAGGGGGGGCTCTGGAAGGAGCAAAATCACA 












This study originally intended to design new plasmid DNA expression vectors for the 
purpose of targeted gene delivery. The strategy involved the design of new synthetic 
promoters/enhancers, upstream of a gene of interest, using regulatory elements 
associated with the expression of a specific target tissue/organ. The goal o f such gene 
delivery was to correct either an inherited genetic or metabolic disease within a specific 
target organ (i.e. targeted gene therapy).
Using the computer analyses, the transcription-binding sites associated with the liver 
(i.e. the target organ) were first identified. Next, from the population of the identified 
hepatocyte-specific transcription factors (see CHAPTER 3 Result 1), HNF4 was 
chosen for the purpose of the present study.
Based on the mechanisms of stable latent replication and extrachromosomal persistence 
o f the 172 kb human herpesvirus EBV, the episomal EBV-based vector was chosen as 
the plasmid DNA delivery system. The functional components required for the 
episomal persistence of EBV-based vectors are the EBV latent origin of replication 
{oriP) present in cis and expression of the viral protein EBNA-1. The EBNA-1 protein 
binds to the family of repeats (.FR) element, a tandem array of 20 repeats of a 30 bp 
motif within oriP, and this association promotes nuclear retention. Another region of 
oriP, the dyad element, acts as the latent replication origin of EBV. Incorporating the 
oriP elements into plasmid vectors has been shown to allow constructs to remain stably 
episomal for long periods of time (Yates et al, 1985).
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Next a tandem array of 1, 3 or 5 repeats of the 12 bp HNF-4 binding site was inserted 
upstream of the luciferase gene within the EBV-based vector p706. To allow the 
expression of the luciferase gene, the SV40 promoter fragment of pGL3 promoter 
vector (Promega, UK) was inserted downstream of the HNF-4 binding sites. The 
p706/HNF4/SV40 reporter vectors were then transfected in both liver-specific HepG2 
and non-liver HtTA-1 cell lines. The results revealed several unexpected findings:
> Firstly the luciferase expression in cells transfected with p706/SV40 was 
significantly higher in HepG2 cells when compared with HtTA-1 cells 
suggesting that SV40 promoter of pGL3 could be used as a liver-preferential 
promoter, as it stimulates preferentially the transcription of the luciferase gene in 
a liver-specific cell line. Secondly the computer analysis revealed the presence 
o f a DNA sequence resembling the liver-enriched C/EBP transcription factor- 
binding site within the SV40 DNA fragment, indicating that this binding site 
might be a functional site and therefore it can at least in part, contribute to 
stimulation of the HepG2-preferential expression of the luciferase gene. 
However this needs to be confirmed for example by performing a DNA 
bandshift assay that will monitor the formation of a complex between a radio­
labelled oligonucleotide containing the C/EBP-resembling sequence of SV40 
promoter and the HepG2 protein extracts. Alternatively, a Dnase I foot print 
assay will reveal whether this element is functional.
> Secondly, the presence of HNF-4 elements decreased significantly the basal 
level of luciferase activity under the control of SV40 promoter especially in 
HepG2 cells, suggesting that HNF-4 might act as a repressor. The comparison
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of this data with the literature revealed that there are few studies showing that 
HNF4 could act as a gene repressor (see INTRODUCTION section 1.1.5.). 
For example Chowdhury et al (1996) in an attempt to elucidate the mechanisms 
governing liver-specific transcription of the liver arginase gene, found 
unexpectedly that the liver-type arginase promoter activity stimulated by 
C/EBPs was repressed by another liver-enriched transcription factor HNF-4. 
The authors speculated that HNF-4 might be involved in fine regulation of the 
arginase gene in the liver. In the present study, it could be hypothesized that the 
binding of HNF-4 to the binding sites created within the p706 vector could 
repress the SV40 promoter activity by suppressing the C/EBP-mediated 
stimulation of the luciferase activity in HepG2 cells. However further in-depth 
investigations are necessary to confirm this hypothesis.
In the light of the above data, it was clear that HNF-4 was not an ideal liver-enriched 
candidate for the liver-directed gene expression. Recent literature within this field 
reveals more and more that liver-specific genes are regulated in an extremely 
complicated manner (see INTRODUCTION section 1.1.5.). Indeed the previously 
thought liver-specific fraws-activators are now shown in several instances to repress the 
transcription of liver-specific genes that are activated by other liver-enriched 
transcription factors (Gregori et al, 1993; Gregori et al., 1994, Kritis et al., 1993; 
Piaggio et al., 1994; Rouet et a l , 1995; Chowdhury et al., 1996). In addition there are 
now numerous examples of studies where liver-enriched transcription factors negatively 
regulate other genes. An example of negative HNF-4 regulation is the mitochondrial 
HMG-CoA synthase gene. HNF-4 binds to the mitochondrial HMG-CoA synthase
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nuclear receptor response element and represses peroxisome proliferator activated 
receptor (PPAR)-dependent activation of reporter gene linked to the mitochondrial 
HMG-CoA synthase gene promoter in HepG2-cotransfected cells (Rodriguez et a l , 
1998). Another example of negative regulation by HNF-4 is the acyl-CoA oxidase 
gene. Both PPARa and HNF-4 efficiently bind to the acyl-CoA oxidase gene enhancer 
element, but PPARa exhibits much stronger transactivation than HNF-4. As a result, 
HNF-4 suppressed the gene-activating function of PPARa, when they were expressed 
together, due to competition for a common binding site (Nishiyama et a l , 1998). 
Furthermore, liver gene regulation studies have illustrated basic principles observed for 
other cell differentiation systems i.e. m-regulatory systems are modular, typically 
including a cluster of binding sites for both cell-restricted and ubiquitous transcription 
factors. None of the cell-specific factors are restricted to hepatic cells, indicating a 
more complex mode of action, in which a unique combination o f regulators, often 
working synergistically, defines a particular phenotype. The simultaneous presence of 
multiple transcription factors may also be required in the response to extracellular 
signals. This combinatorial mode of regulation is not specific to the liver, but rather it 
is a common theme in many mammalian cell differentiation systems (Cereghini, 1996). 
Another common feature is that a single m-acting element can interact with a family of 
transcription factors displaying similar DNA binding specificity, often coexisting in the 
same cell. Conversely, single transcription factors appear to serve multiple 
developmental functions in the organism (see INTRODUCTION section 1.1.5.). 
Moreover, the organization of the chromatin structure and its reorganisation during 
development, certainly play a critical role in gene activation. Studies with transgenic
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mice have shown that while relatively small promoter regions define liver-specificity 
and hormonal regulation in cultured cells, often distal enhancers are required to 
reproduce the in vivo endogenous expression (e.g. Cuif et al., 1992). The homo- and 
heterodimerization between members of a particular transcription factor family adds 
another level of complexity not yet understood (see INTRODUCTION section 1.1.5.). 
Additional determinants of specificity that remain to be further investigated include 
protein-protein interactions, cell-specific coactivators or cofactors, protein 
modifications, competitive interaction or synergy o f factors bound nearby or in close.
In the second part of this thesis, efforts were concentrated on identification of a gene 
which, was expressed at unusually high level in the target tissue (liver) and then to use 
the promoter for this gene to drive the expression of the luciferase reporter gene to 
mimic a therapeutic gene in the target tissue. Since HO-1 gene is known to be highly 
expressed in the liver, it was logical to use the promoter of this gene for the purpose of 
this study. In addition the p706 reporter constructs that were obtained from the Prof. 
Tyrrell’s laboratory contained originally the 4.7 kb of the human HO-1 5’-flanking 
region (i.e.plasmid p706/HO4.7). In addition this laboratory possessed an array of 
p706/HO derived plasmids that was constructed following a series o f sequence 
deletions within the 4.7 kb of the 5’-flanking region linked to the luciferase gene.
The first step was to explore the basal regulation of the gene expression to gain insight 
into the mechanism of tissue-preferential HO-1 gene regulation. To identify the ex ­
acting elements that regulate basal human HO-1 gene expression, reporter plasmids 
containing deletions within the specific HS regions of 4.7 kb of the human HO-1 5’-
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flanking region linked to the luciferase gene in p706 vector were transiently transfected 
into human carcinoma cell lines HepG2 and Hela cells. Since the 5’-flanking region of 
human HO-1 is not as well studied as in mouse, a data base program called TFSEARCH 
was used to locate the transcription factor elements in the 4.7 kb of the 5’-flanking 
region. The transient transfection assays confirmed that the expression of the luciferase 
reporter in p706/HO4.7 construct is preferentially higher in HepG2 cells when 
compared to the non-liver cell line HtTA-1. Furthermore it appeared that the HS-3 
region (position -4080 to -3650) that contains the region homologous to SX2 mouse 
enhancer is critical for such tissue preferential expression of luciferase in HepG2 cells. 
This region contains the previously identified human Cd+2RE. (Takeda et al., 1994). 
Furthermore the computer analysis reveals that this region contains sequence 
resemblance to several critical c/s-acting elements such as the liver enriched C/EBPp, as 
well as important elements such as NF-E2 and AP-1 a and AP-1 b (see Appendix 5.3.2. 
CHAPTER 5 Result 3). Also the comparison of p714 mutant construct with p717 and 
p718 strongly suggest that the region -380 to +1 where the HS-1 and HS-2 regions are 
located contains liver-preferential negative regulatory elements. The precise nature of 
these negative regulatory elements need to be investigated by methods such as bandshift 
and Dnase I foot print or chromatin immunoprecipitation (chip) assay. However within 
the context of the present study, this negative regulatory region coincided with the HS-2 
region containing the highly polymorphic (GT)n repeats, that is known to negatively 
regulate the gene transcription (Yamada et al., 2000). So one possibility is that these 
dinucleotide repeats influence the expression of luciferase in the p714-transfected cells 
as these dinucleotides repeats are thought to act as a repressor of the human HO-1
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transcriptional activation (Kimpara et al, 1997). Furthermore, since the number of 
these repeats appears to influence the level of modulation of gene expression, the GT 
repeats within the 4.7 kb fragment was carefully monitored following sequencing and 
was found to be around 29 GT repeats. This number GT repeats could be classified as 
class ‘M’ (25-29 repeats, medium) according to the study by Yamada et al (2000). The 
recent study by Takahashi et al (1999) that assessed the 4 kb of the 5’-flanking region 
o f the human HO-1 for basal activity in both HepG2 and Hela cells, does not report 
such a negative regulatory region within the first 380 bp upstream promoter region of 
HO-1 presumably because of the low number of such GT repeats in their constructs. 
Indeed, the sequencing performed by these authors (i.e. approximately 2 kb of the 5’- 
flanking region) reveals that the number of GT repeats within their constructs is only 
around 23 that according to the classification by Yamada et al (2000) falls into the 
category ‘S’ (small, < 25 repeats). Takahashi et al, (1999) also reported a positive 
regulatory region at position -1976 to -1655 bp that functioned only in HepG2 cells but 
not in Hela cells. Unfortunately because of the original design of the p706/HO vectors 
in Prof. Tyrrell’s laboratory (constructs considering the role of HS regions in HO-1 
expression), it was not possible to compare this data with the present study as this 
region was consistently deleted in the p706/HO mutant constructs. The only construct 
that contained this region was p736, but this construct also contained more than 3 kb 
undeleted sequence when compared to other mutant constructs. So it is clear that 
further analyses are necessary to draw any conclusion concerning this positively 
regulated region.
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Overall, it appears that the 4.7 kb of the 5’-flanking region of human HO-1 can be used 
as a liver-specific promoter/enhancer sequence to drive expression of other genes in the 
liver. However further detailed functional analyses are necessary to understand the 
liver-HO-1 gene regulation and also to identify the most liver-specific c/s-acting 
elements within the 5’-flanking region of human HO-1 gene.
6.1. Future Work
As mentioned previously, liver-specific genes are regulated in an extremely 
complicated manner. So it is hard to design functional synthetic specific promoters for 
tissue-targeted gene delivery. Although the approach used in this study was carefully 
planned, the outcome of the data clearly indicated that choosing a single liver-enriched 
transcription factor binding site even in tandem repeat is overenthusiastic. The future 
project should therefore consist of using the data obtained from the TFSEARCH 
analyses of the present study in order to select a group of transcription factor binding 
elements for the design of synthetic liver-enriched promoters. A recent study by Li et 
al, (1999) has described a strategy for the construction and characterization o f synthetic 
muscle promoters, whose transcriptional potencies in terminally differentiated muscle 
greatly exceeded those of both the natural myogenic skeletal a-actin gene promoter and 
viral promoters. This has been achieved by random assembly of specific muscle- 
specific transcription binding sites into synthetic promoter recombinant libraries, and 
screening of hundreds of individual clones for transcriptional activity in vitro and in 
vivo. A similar approach should be applied to continue the present study by for
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example random assembling different combinations of liver-enriched HNF-1, HNF-3, 
HNF4, HNF6, C/EBP and DBP transcription factor binding sites.
The HO— 1 sequence deletion mutants in the present study were designed around the 
role of HS sites. However in order to elucidate the regulation of the human heme 
oxygenase-1 (HO-1) gene expression as an attempt to understand the mechanism of 
hyperoxic and tissue-preferential HO-1 gene regulation, a new series of progressive 
deletion mutants of the 5’-flanking region linked to a reporter gene has to be 
constructed. Also it is necessary to use more liver- and non-liver specific cell lines as 
models to obtain the true comparison between the c/s-acting regulatory elements that 
are liver-specific and those elements that are not. The (GT)n dinucleotide repeat in the 
5'-flanking region of human HO-1 gene shows length polymorphism and appears to 
modulate the level of liver specific gene expression. So further investigations could 
include analysis of the number of these repeats through either a series of small scale 
deletions within this region or through insertion of synthetic oligonucleotides containing 
additional repeats.
Furthermore, most of the researchers have used approximately 4 kb of the 5'-flanking 
region of the human HO-1 gene to assess the promoter activity. Bioinformatic research 
analysis database program TFSEARCH could be used to allocate the transcription 
factor elements within the 10-13 kb of the 5' flanking region. Bandshift and DNase I 
footprint assays could then be carried out to further identify these sites. It will also be 
important to clone the 10-13 kb upstream region in p706-based EBV-vectors to identify 
the critical liver-specific region within the 5’-flanking o f human HO-1 gene.
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Furthermore the previous identification o f HS-sites was performed with the method 
developed by Wu (1980). This method lacks precision, so the positions of each HS site 
are an approximation. Recently McArthur et al, (2001) has designed a precise 
methodology that allows the quantification of the sensitivity of chromatin to digestion 
by Dnase I using real-time PCR. This approach has three clear advantages over the 
more conventional use of Southern hybridization assay: (a) the accuracy of 
quantification is improved; (b) the resolution of the assay is enhanced, by designing 
primers to amplify small amplicons it is possible to analyse sequences both coincident 
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